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ABSTRACT 
 
 The sensing of lipopolysaccharide (LPS) represents a major mechanism of detection of 
Gram-negative bacterial infection by the human innate immune system.  This pathogen 
associated molecular pattern is recognized by the host through the transmembrane pattern 
recognition complex comprised of Toll-like receptor 4 (TLR4) and myeloid differentiation 
antigen (MD-2).  As described in Chapter 1, LPS-dependent complex formation of TLR4/MD-2 
heterodimers results in the activation of pro-inflammatory signaling cascades.  Although 
inflammation is usually host protective, when uncontrolled it can cause host fatality through 
sepsis.  The function of soluble or membrane anchored human CD14 is to bind and shuttle LPS 
to TLR4/MD-2, thereby enhancing host sensitivity of LPS.  The mechanism by which CD14 
binds and transfers LPS remains unknown, and our understanding of this process would be 
advanced by structural information. 
 Thus, we determined the x-ray crystal structure of human CD14, the results of which 
were recently published (Kelley, S.L., et al., (2013). J. Immunol. 190:1304-1311) and are 
presented in Chapter 2 of this dissertation.  To do so, we cloned, expressed, and purified two 
constructs of human CD14 from a mammalian expression system.  One of the two crystallized 
and resulted in an x-ray crystal structure solution.  The structure of human CD14 reveals a bent 
solenoid with an N-terminal hydrophobic pocket.  Compared to the mouse CD14 crystal 
structure, human CD14 reveals an expansion of residues comprising the rim region and an 
adjacent, solvent exposed hydrophobic patch, which may facilitate LPS binding.   
 In Chapter 3 we describe the expression and purification of mouse CD14 as an additional 
target for ligand binding crystallization studies.  After determining that purified human and 
mouse CD14 bind LPS and other ligands using native PAGE gel shift and ForteBio Octet assays, 
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we confirmed the bioactivity of both purified proteins through cell-based stimulation assays.  
Additional small gel filtration mixing studies (Ranoa, D.R., Kelley, S.L., et al. (2013). 
J.Biol.Chem. 288: 9729-9741) confirmed the ability of our purified human CD14 to shuttle 
triacylated ligands to the Toll-like receptor 2 complex.  Chapter 3 also describes our efforts to 
produce a ligand bound structure of CD14. 
 An additional project, described in Chapter 4, focuses on a predicted Toll-like receptor 4 
accessory protein called Der p 2.  Der p 2 is an aeroallergen from Dermatophagoides 
pteronyssinus house dust mites, which has been implicated as an MD-2 analogue.  By binding 
LPS and TLR4 in place of MD-2, Der p 2 may activate pro-inflammatory signaling and stimulate 
IgE production and allergic reaction, most often associated with allergic asthma.  In 
collaboration with the lab of David Kranz (University of Illinois, Urbana), we used yeast display 
to create Der p 2 and MD-2 full length Aga2 fusion proteins.  After verifying yeast surface 
expression, we assessed protein folding by characterizing the ability of Der p 2 and MD-2 to 
bind anti-Derp2 and anti-MD-2 monoclonal antibodies, respectively, in thermal denaturation 
studies.  Flow cytometry assays indicate that Der p 2 binds biotinylated and non-biotinylated 
forms of LPS without detectable binding to purified human TLR4.  Clinically, we found that this 
system provides a novel assay that reliably and quantitatively detects anti-Der p 2 IgE in serum 
and plasma samples of atopic patients.    
 Chapter 5 summarizes our findings, describes their significance, and suggests avenues for 
future work.  Although a ligand bound structure of CD14 has not yet been determined, we have 
successfully determined the x-ray crystal structure of human CD14, which significantly enhances 
our understanding of the LPS binding pocket.  The CD14 structure and our ligand binding 
crystallization efforts may foster additional ligand binding structural studies, virtual docking 
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studies, and drug design efforts thus allowing therapeutic intervention at an early step in the 
signaling cascade.   Additionally, we utilized yeast display and flow cytometry to detect binding 
of Der p 2 to LPS and created a novel system for the detection of anti-Der p 2 IgE antibodies in 
serum and plasma.  Additional mutational analysis of Der p 2 could determine the contribution of 
individual amino acids to LPS binding and also natural epitopes of anti-Der p 2 IgE, thereby 
creating new targets for drug development to treat allergic asthma.  In total, our efforts have 
advanced our understanding of host LPS detection during bacterial infection and allergy through 
structural and ligand binding studies of the TLR4 accessory proteins human CD14 and Der p 2. 
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CHAPTER 1: 
Innate Immune System 
 
1.1 Innate and Adaptive Immunity 
Bacteria, viruses, fungi, and other infectious microorganisms come into contact daily 
with potential human hosts.  These agents exploit niches in the host in order to acquire resources 
for viability and reproduction.  To counteract the drain on resources and health hazards created 
during these encounters, immune systems capable of detecting and destroying foreign invaders 
have evolved in all multicellular organisms.  Humans and other vertebrate immune systems can 
be subdivided into two branches:  innate and adaptive.  Both branches of the immune system 
work together to detect and remove threats to host health, and to heal the damage inflicted by the 
invader and the associated host inflammatory response. 
 The innate immune system of all multicellular organisms encompasses heritable 
mechanisms for sensing microorganisms, provides an immediate host protective response to an 
invasion, and helps activate the adaptive immune system.  To achieve all of these goals, the 
human innate immune system is complex.  Physical, chemical, and mechanical barriers, such as 
skin, epithelial cell tight junctions, salivary enzymes, low gut pH, and mucosal movements, exist 
to prevent invader entry.  If these barriers are surpassed, diverse families of germ-line encoded 
soluble or transmembrane pattern recognition receptor proteins (PRRs) are present to sense 
microbes. 
 When the idea of PRRs was introduced by Dr. Charles Janeway at a Cold Spring Harbor 
symposium, he described the conserved molecular patterns recognized by PRRs as pathogen-
associated molecular patterns (PAMPs) (1).  PAMPs are present either in the microbes 
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themselves or in their particulate matter.  The PAMP recognition process is considered more 
‘non-specific’ than other types of immune recognition processes, because each PRR can 
recognize multiple ligands from various microorganisms.  PRRs are often subdivided into 
families based on structural homology and PAMP recognition.  One such PRR family that we 
study are the Toll-like receptors (TLRs) (2). 
 Working in concert with other components of the innate immune system, PRRs trigger 
signaling cascades, enabling the activation of a range of innate immune cells, including 
macrophages, mast cells, dendritic cells, neutrophils, and a variety of stromal cells.  Signaling 
stimulates humoral defenses, such as production of cytokines, chemokines, and nuclear 
transcription factors, leading to an immediate, yet nuanced immune response that includes host 
inflammation to attract and activate additional immune cells for invader killing and clearance 
and cellular events leading to the activation of the adaptive immune system (2). 
 The human adaptive immune system is equally complex.  Macrophages and dendritic 
cells are primary antigen presenting cells, responsible for the processing and presentation of 
antigens derived from the invader.  Upon receptor mediated recognition of the antigen, adaptive 
immune cells, such as CD4+ helper T cells, CD8+ cytotoxic T cells, and antibody producing B-
cells, can be activated.  Although the activation of the adaptive immune response is relatively 
slow, initiating days after the innate immune system begins to respond to an invading pathogen, 
the adaptive immune response is equally critical for host health because it creates highly specific 
humoral effector molecules, such as antibodies, targeted to the invader.  Using memory cells, 
adaptive immunity also provides a long-term immunological memory response that is rapidly 
activated upon reinfection (2). 
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1.2 Lipopolysaccharide 
The detection of bacterial lipopolysaccharide (LPS, endotoxin) is the quintessential 
example of the power of Toll-like receptor PAMP recognition (Figure 1.1).  The discovery of 
LPS is rooted in the finding that bacterial components stimulate fever and other symptoms in 
mammals.  Prior to 1886, no one knew what microbial component was responsible for inducing 
the fever response.  During that year, Ludwig Brieger discovered heat-labile protein toxins in the 
culture supernatant of Gram-positive C. diphtheria bacteria.  Because this type of toxin was 
secreted thereby physically separated from the original microbe, it was later renamed ‘exotoxin.’  
Although Gram-negative Vibrio cholerae infection produced a similar pyrogenic fever response, 
studies of V. cholerae cell supernatant did not identify a classical exotoxin.  In 1894, while 
working with V. cholerae immunized guinea pigs, Richard Pfeiffer found the animals would still 
die upon inoculation despite the fact that there was no detectible V. cholerae bacteria in the gut.  
Further experiments by Pfeiffer’s showed cell membrane containing insoluble fractions of 
heated, lysed V. cholerae maintained the ability to kill, suggesting the existence of a new type of 
heat-stable toxin that was liberated from the cell itself during lysis.  Pfeiffer called this integrated 
microbial toxin ‘endotoxin’.  Lipopolysaccharide was revealed as endotoxin following extensive 
purification, structure determination, and chemical synthesis experiments (3). 
Lipopolysaccharide is essential for the survival of Gram-negative bacteria and is the 
major outer membrane lipid component, with each bacterium containing approximately 106 
molecules of LPS (4).  As an amphipathic molecule, LPS contains hydrophobic fatty acid tails 
and hydrophilic sugars and phosphate residues, which are organized into three structural and 
functional regions: (a) a highly variable, repeating oligosaccharide (O-antigen), (b) additional 
sugars (core), and (c) a glycosylated phospholipid (lipid A) (Figure 1.2A) (5).   
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In the model Gram-negative bacterium species Escherichia coli, lipid A contains a 
hexaacylated β(1-6) diglucosamine backbone flanked by two phosphate groups at positions 1 and 
4’(Figure 1.2A) (5).  Since lipid A is responsible for anchoring LPS in the bacterial outer 
membrane, it is typically hidden from immune detection. When lipid A is released during 
bacterial cell division or death, it becomes detectable as an endotoxin.  In fact, the lipid A portion 
of LPS is capable of stimulating human cell activation to the same extent as full length LPS (6).  
Injection of picogram levels of purified or synthetic lipid A also stimulates antibody production 
and inflammation as much as full length LPS, leading to phenotypic fever and lethality in 
C57BL/6 mice (7).  Likewise, bacteria defective in lipid A synthesis cause less inflammation and 
endotoxic shock in animal models (8). 
Although the presence of LPS is conserved in Gram-negative bacteria, the length and 
sugar content of the core and O-antigen regions can greatly vary between and within a species.  
For example, E. coli and other pathogenic bacteria produce smooth to rough (Ra to Re) 
chemotypes, modulating the serological specificity of their cell wall (Figure 1.2A) (5).  Smooth 
E. coli LPS contains the full complement of O-antigen and core sugars, making colonies formed 
by these bacteria on agar appear smooth.  Rough mutants of E. coli produce LPS containing lipid 
A, but omitting either the complete O-antigen (in the Ra form) or both the O-antigen and 
increasing amounts of the core polysaccharide region (in Rb to Re forms) (Figure 1.2A). Rough 
mutants form bacterial colonies with rough edges when plated on agar.  Most commercially 
available preparations of smooth LPS also contain rough precursor forms of LPS (9) and may 
contain lipoproteins (10).  Variation and modification of the O-polysaccharide can also play a 
role in immune evasion (8).   
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Similarly, the length, number and saturation of lipid A fatty acid tails can vary.  
Hexaacylated E. coli lipid A most strongly stimulates inflammatory immune signaling (5).  
Stimulation using tetraacylated E. coli lipid IVa (Figure 1.2B), a biosynthetic precursor of 
hexaacylated E. coli lipid A, produced a differential effect in mice and humans.  In mice, lipid 
IVa is a weak agonist, but lipid IVa acts as an antagonist in humans (11, 12).  Triacylation and 
pentacylation are also represented in various bacterial species, resulting in either loss of activity 
or antagonism (12-16).   
Variation of the fatty acid content of lipid A between different bacterial species, or even 
within the same species, is also a bacterial virulence strategy.  For example, the human pathogen 
Helicobacter pylori subverts complete activation when in the stomach by producing a 
pentaacylated form of lipid A that lacks the 4’ phosphate group (17).  The most striking example 
of modulation of fatty acid content is the causative agent of plague, Yersinia pestis, which is 
capable of changing from hexacylated LPS when grown at ambient temperature (26oC) to 
tetracylated LPS when grown at 37oC.  This temperature shift reflects the change in environment 
as Y. pestis moves from the flea vector to the mammalian host and enables this pathogen to evade 
sensing by the human innate immune system (18, 19). 
 
1.3 Lipopolysaccharide Binding Protein (LBP) 
 The central pathway used by cells to detect LPS involves a series of LPS-receptor 
interactions (Figure 1.1).  The requirement for a receptor-ligand interaction step to sense LPS 
was inferred by the exquisite sensitivity of LPS sensitive cells to detect picogram levels of 
endotoxin (7, 20).  Initial efforts to identify mammalian proteins capable of binding LPS first 
revealed lipopolysaccharide binding protein (LBP).  LBP is a 60 kD serum glycoprotein 
6 
 
produced primarily by liver hepatocytes and secreted in blood at levels of 5-15 g/mL (21, 22).  
As an acute-phase protein, the concentration of LBP in serum can increase more than 30 fold 
during an infection (23). 
 In 1990, the sequence of LBP was determined from cDNA clones, making LBP a 
founding member of the BPI/LBP/PLUNC-like lipid-binding protein family (22).  Although the 
structure of LBP has not yet been solved, a 2.4 Å resolution structure of another family member, 
bactericidal permeability increasing (BPI) protein, was determined in 1997 by Beamer and 
colleagues (24).  BPI is produced by neutrophils, and has an anti-inflammatory role of binding 
and neutralizing LPS (25, 26).  Since BPI and LBP share 50% sequence identity, the structure of 
LBP is often modeled off of the structure of BPI (30,32).  The structure of BPI revealed an 
extended two domain boomerang-shaped protein fold (25, 27) containing the acyl chains of two 
co-purified phospholipids bound in two hydrophobic pockets in the N-terminal pocket (24, 26).  
Thus, the N-terminal pocket of LBP is hypothesized to accommodate the lipid A region of LPS 
and stabilize lipid A phosphates using conserved basic amino acids (24, 25).  Biophysical 
measurements using fluorescently labeled LPS (28, 29), sucrose density gradients with 
radioactively labeled LPS (28), and native polyacrylamide gel shift studies (30) have 
demonstrated the capacity of LBP to disaggregate and catalytically deliver LPS to another 
molecule called CD14. 
 
1.4 Cluster of Differentiation Antigen 14 (CD14) 
 The focus of our structure determination effort, described in Chapter 2, is the next 
endotoxin receptor in the central LPS sensing pathway, cluster of differentiation antigen 14 
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(CD14).  CD14 was initially identified using two different monoclonal antibodies (anti-My4 and 
AML-2-23) as a cell differentiation marker in normal myeloid lineage and acute myeloid 
leukemia (AML) cells, leading to the initial complication of dual naming as both My 4 (31) and 
My23 (32).  Isolation of milligram quantities of CD14 protein from the urine of nephrotic 
patients allowed Bazil and coworkers to conduct comparative studies, including antibody 
binding, N-terminal sequencing, amino acid composition, native polyacrylamide gel molecular 
mass and pI estimation, to conclude that My4 and My23 were inherently the same protein (33).  
From these findings, the 3rd International Workshop and Conference on Human Leukocyte 
Differentiation Antigens adopted the cluster of differentiation nomenclature CD14 (34). 
CD14 is encoded by a single gene localized to human chromosome 5 (35) and mouse 
chromosome 18 (36).  Both species share 73% sequence identity in their coding regions, and 
both species are capable of creating both membrane-bound and soluble protein products (Figure 
1.1).  Membrane CD14 (mCD14) is a ~55 kDa glycophosphatidylinositol (GPI) anchored 
glycoprotein (37, 38) that is highly expressed on monocytes, macrophages, and neutrophils with 
lower surface expression observed on a variety of other hematopoietic and stromal cells.  Soluble 
forms of CD14 (sCD14) exist in serum, cerebrospinal, and other body fluids.  Soluble CD14 is 
generated by at least three different mechanisms, which include bypassing GPI addition, 
cleavage of the GPI anchor by phospholipase D, or direct proteolysis from the cell surface (39, 
40). 
The primary role of CD14 is to concentrate low levels of LPS to increase cellular LPS 
sensitivity by binding and delivering LPS directly to the Toll-like receptor 4 (TLR4) signaling 
complex (28, 30, 35, 40, 41), which will be discussed in detail in the next section of this chapter.  
In concert with LBP, small gel filtration mixing studies have demonstrated a catalytic role for 
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CD14 in the delivery of LPS to the TLR4-MD2 complex (42-45).  Membrane CD14 shuttles LPS 
to TLR4 complexes in a two dimensional search (40); whereas, sCD14 enables cells that lack 
endogenous mCD14, including most epithelial and endothelial cells, to respond to LPS (46).  
Both soluble and membrane CD14 are capable of binding LPS over time, or as discussed earlier 
in this chapter, CD14-LPS complex formation can be catalyzed by LBP (28-30).  The protein-
protein interactions involved and mechanism required for LPS transfer from LBP to CD14 are 
still unknown. 
  CD14-mediated  delivery of Gram-negative bacterial LPS stimulates TLR4 activation, 
initiating host inflammation by driving cellular production of pro-inflammatory mediators, 
including cytokines, chemokines, and cell adhesion molecules (47).  However, as a pattern 
recognition receptor, CD14 has additional functions beyond LPS-dependent signaling.  For 
example, CD14 can act as a phagocytic receptor for whole bacteria or aggregates of LPS that 
have been opsonized by LBP, thereby clearing infection and reducing inflammation (48-52).  
Soluble CD14 is also able to bind and shuttle host phospholipids (53-55).  In addition to LPS, 
CD14 also enhances cellular inflammatory responses to a wide variety of acylated ligands from 
Gram-negative and Gram-positive bacteria, including lipoproteins, lipoteichoic acid (LTA), 
mycobacterial lipoarabinomannan (LAM), and atypical lipopolysaccharides, which stimulate 
pro-inflammatory signaling through the Toll-like receptor 2 (TLR2) subfamily (56-66). 
At the local site of infection and at low levels systemically, inflammatory signaling is 
protective and results in the clearance of invading bacteria.  However, large scale signaling or 
systemic bacterial infection can actively propagate dysregulated pro-inflammatory signaling, 
causing fatality through sepsis (65, 66).  CD14 deficient mice have greatly diminished levels of 
pro-inflammatory cytokines and have lessened symptoms of septic shock, which typically 
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present in mice as lethargy, breathing trouble, and ruffled fur.  Likewise, CD14 deficient mice 
survive when challenged with otherwise lethal doses of LPS or live E. coli bacteria (67).  CD14-
knockout mice affirm the importance of CD14 in the TLR4/MD-2 pro-inflammatory signaling 
pathway because both TLR4 and MD-2 deficient mice are also highly resistant to shock induced 
by low doses of LPS or Gram-negative bacteria (68).  Given this central role in TLR agonist 
delivery, CD14 is an obvious drug target for the treatment of sepsis (65, 66).   
As described in Chapter 2, we produced and purified human CD14 for x-ray 
crystallography.  Our solution of the x-ray crystal structure of human CD14 confirms the 
presence of a hydrophobic cavity near the N-terminus, which could provide a binding pocket for 
LPS.  In Chapter 3, we describe efforts produce mouse CD14 protein to obtain a ligand bound 
crystal structure of either human or mouse CD14.  We used native polyacrylamide gel shift and 
ForteBio Octet techniques to confirm the ability of both CD14 proteins to bind ligands and 
utilized an IL-8 bioactivity assay to confirm the ability of both proteins to deliver LPS to 
stimulate cell signaling.  Although we were able to produce single crystals of native CD14, 
diffraction quality liganded CD14 crystals did not develop for either construct.  Our comparison 
of our human CD14 structure and the previously published x-ray crystal structure of mouse 
CD14 (69) provided additional insight into the N-terminal LPS binding sites of both proteins.  
For example, we identified a hydrophobic surface near the rim of the binding pocket that may 
stabilize hydrophobic residues in LPS fatty acid tails not accommodated by the amino terminal 
cavity.  Additionally, we identified an expanded pocket rim region in our structure that led us to 
hypothesize that the previously determined rim region in mouse CD14 is expanded and the 
hydrophobic rim residues in human and mouse CD14 may shift to accommodate the fatty acid 
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tails of LPS during ligand binding.  These findings may encourage new therapeutic efforts 
targeting the structure and function of human CD14 in the treatment of sepsis.   
 
1.5 Toll-like Receptor 4 Complex (TLR4/MD-2) 
 The terminal receptor in the central pathway of LPS sensing is the TLR4 signaling 
complex (Figure 1.1).  In 1997, Bruce Beutler discovered the function of TLR4 was to act as the 
transmembrane receptor required for LPS sensing (68), earning him the Nobel prize in 2012.  
The gene encoding TLR4 and its role to transfer the LPS binding event across the cell membrane 
to stimulate signaling were first determined by studying C3H/HeJ mice, which were resistant to 
LPS despite the fact they had normal levels of CD14 (70, 71).  Genetic mapping studies revealed 
the defect in TLR4 protein was due to a single missense point mutation (P712H) in the TLR4 
gene (68).  Additional evidence for the role of TLR4 was provided by targeted knock out of 
TLR4 in mice, which are also hyporesponsive to LPS (68, 72, 73).   
 TLRs were named Toll-like because they are orthologous to the Toll receptor found in D. 
melanogaster, which enables the fruitfly to detect the presence of fungal infections (74) and to 
establish the dorsal-ventral axis during embryogenesis (75).  Each TLR protein in humans is 
encoded by one of ten TLR genes and named TLR1 through TLR10.  TLRs are produced in 
multiple cell types and tissues, including lymphocytes, macrophages, dendritic cells, lung, 
kidney, small intestine, stomach, and reproductive tissues, with varied expression levels for each 
TLR (6).  For example, the TLR4 gene is expressed in macrophages, but can also be found in 
other leukocytes including dendritic cells, mast cells, neutrophils, eosinophils and natural killer 
cells (2). 
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The structure of TLR4 represents the strong structure-function relationship typical of all 
TLRs.  When we initiated our work, only a handful of crystal structures of TLRs or their 
accessory proteins had been solved.  Now, ~30 human and mouse TLR x-ray crystal structures, 
including the ligand bound extracellular domains of TLRs 1, 2, 3, 4, 5, and 6 (76-80) and the TIR 
domains of TLRs 1, 2, and 10 (81, 82) have been determined.  Although the crystal structure of 
the extracellular and transmembrane domains of TLR10 and its natural ligand have not yet been 
determined, our lab has discovered that TLR10 can cooperate with TLR2 to sense triacylated 
lipoprotein PAMPs from bacteria, though TLR10 does not share common signaling pathways 
with TLR2/1 (83).   
Generally, TLRs fulfill two major functions: binding PAMP ligands and signaling the 
binding event across a membrane.  Ligand-dependent dimerization of TLRs stimulates the 
production or modulation of pro-inflammatory mediators like interleukins, cytokines, 
chemokines, adhesive proteins, tumor necrosis factor alpha (TNF-α), tissue factors, and co-
stimulatory molecules of the adaptive immune system (6, 84, 85).  To accomplish these 
functions, all TLRs are transmembrane receptors comprised of an N-terminal extracellular 
domain, a type I transmembrane domain, and C-terminal cytoplasmic signaling domain (86). 
 The N-terminus of TLR4 constitutes the extracellular ligand binding domain.  This 
domain in TLR4 contains 19 leucine rich repeats (LRRs), though other TLRs can have as many 
as 25 LRRs.  The repetitive leucine rich sequence that creates the bent arc or solenoid LRR 
protein folding motif was first identified in 1985 (87, 88).  Each LRR of TLR4 forms a single 
coil or loop of the solenoid comprised of a leucine rich beta strand, helix, and surrounding loops.  
Tandem repeated LRR coils form a solenoid fold which is bent with a leucine rich parallel beta 
sheet forming the concave face of the solenoid.  Additionally, leucine, phenylalanine and other 
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hydrophobic side chain residues, which vary greatly in sequence in the helical and turn region on 
the convex side, are buried in the interior of the coil.  The fold is stabilized by hydrophobic beta-
beta interactions and bridging hydrogen bonds between asparagine residues (6).  The solenoid 
fold can be further subdivided into a central region and two capping regions at the N and C-
terminus of the extracellular domain. These capping regions vary in length and degree of rotation 
relative to the central region.  The N and C-terminal capping regions contain both hydrophobic 
and hydrophilic residues to protect the hydrophobic beta sheet from the hydrophilic extracellular 
milieu (89). 
 The second region of TLR4 is a type I, single pass helical transmembrane domain, which 
is present in all TLRs and serves to transfer the signal derived upon PAMP binding across a 
membrane.  Human TLRs can be subdivided into two groups based upon the cellular location of 
the membrane being spanned.  TLRs 3, 7, 8 and 9 are found in the membranes of intracellular 
compartments, such as endosomes and lysosomes where they sample viral and bacterial nucleic 
acid material that has released following phagocytosis and particle destruction (12).  TLRs 1, 2, 
5, 6, and 10 are present in the plasma membrane and sample the extracellular environment (90).  
For most TLRs, trafficking motifs have been identified in the sequences of the transmembrane 
helix or adjacent residues to direct the receptor to the appropriate membrane (91). Plasma 
membrane TLRs can be internalized to intracellular compartments following receptor mediated 
endocytosis.  For example, TLR4 is internalized in a membrane CD14-dependent manner (92).   
Finally, the third domain in TLR4 is an intracellular, Toll/interleukin-1 Receptor (TIR) 
cytoplasmic domain important for propagating the signal derived from PAMP binding.  The TIR 
domain is named to reflect a shared structural homology with both D. melanogaster Toll and 
human interleukin-1 (IL-1), a pro-inflammatory cytokine produced in macrophages responsible 
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for stimulating chemokine induction, cell maturation, proliferation of B cells, and IL-2 release 
(93, 94).  As mentioned previously, intracellular signaling is propagated by dimerization of the 
TIR domains of two TLRs, but the requisite binding partner varies for each TLR.  For example, 
TLRs 3, 5, 7, 8, and 9 all homodimerize to accommodate their ligands.  As a subfamily, TLRs 1, 
6, and 10 each form heterodimers with TLR2 during recognition of various di or tri-acylated 
bacterial or fungal ligands.  The TLR4 signaling complex is once again unique among TLR 
family members because it not only contains a dimer of two TLR4 monomers to signal, but also 
requires two 25 kD myeloid differentiation antigen (MD-2) accessory proteins in a 
heterotetrameric arrangement to bind its acylated PAMPs (95). 
MD-2 is essential for LPS binding and TLR4 signaling because it provides a hydrophobic 
pocket to accommodate the acyl chains of TLR4 ligands, orienting the ligands in a way that 
enables interactions with TLR4 (95).  Thus, knocking out MD-2 results in the loss of LPS 
signaling (72, 96).  Addition of exogenous, soluble MD-2 to human corneal epithelial cells, 
which are not capable of producing MD-2, permits sensitization to LPS in vitro (97).  Likewise, 
transfection of both MD-2 and TLR4 is necessary to enable non-responsive HEK293 or CHO 
cell lines to respond to LPS (95, 98).   
 A discussion of MD-2 structures, with and without bound ligand, will provide a backdrop 
for better understanding our solution of the human CD14 crystal structure and how it may 
interact with LPS, as described in Chapter 2.  The x-ray crystal structure of human MD-2 was 
solved in 2007 in the absence (2E56.pdb) and presence of a bound E. coli lipopolysaccharide 
ligand precursor called lipid IVa (2E59.pdb) to 2.0 Å and 2.2 Å, respectively (99).  Both native 
and lipid IVa bound structures show that MD-2 contains an immunoglobulin-like fold that is 
conserved among MD-2 like (ML) family members.  The fold consists of one  sheet comprised 
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of three antiparallel  strands and a second  sheet with six antiparallel  strands.  Together these 
two  sheets produce a deep hydrophobic cavity (1,710 Å3) in a clamshell-like fold (99).  MD-2 
also contains three disulfide bonds (C25-C51, C37-C148, and C95-C148) and one free cysteine 
(C133), which can cause disulfide-bond driven protein aggregation during purification steps 
detectable by a ladder-like appearance on protein gels that is abrogated upon addition of a 
reducing agent (100).  Single point mutations of MD-2 at C95Y and Y102A result in complete 
loss of LPS-dependent signaling (98, 101, 102).  Comparison of lipid IVa bound and unbound 
MD-2 structures show that ligand binding does not significantly alter the structure (0.3 Å 
r.m.s.d.).  Positively charged residues at the pocket entrance of MD-2 (K122 and R90) help 
stabilize the negatively charged phosphates of bound lipid IVa, with all four of its fatty acid 
chains completely sequestered inside the pocket. 
   Numerous ligand-bound TLR4/MD-2 structures were solved between 2007 and 2012 
adding to our understanding of TLR4/MD-2 ligand recognition (Figure 1.3).  For example, the 
crystal structures of mouse MD-2 bound to both TLR4 and lipid IVa (3VQ1.pdb; 2.7 Å) (103) 
and human MD-2 bound to lipid IVa (2E59.pdb; 2.2 Å) (Figure 1.3C) (99) have been solved.  
Additionally, the crystal structures of mouse TLR4/MD-2 (2Z64.pdb; 2.84 Å) and human 
TLR4/MD-2 (2Z65.pdb; 2.7 Å), with and without a synthetic tetraacylated TLR4 antagonist 
called Eritoran (Figure 1.3B) (102, 104) were solved.  Most importantly, the x-ray crystal 
structures of homodimeric complexes of mouse TLR4/MD-2 (3VQ2.pdb; 2.5 Å) (103) and 
human  TLR4/MD-2 (3FXI.pdb; 3.1 Å) (Figures 1.3A and 1.3D) (77) bound to different 
chemotypes of E. coli LPS have been determined.   
 Both human and mouse species share greater than 60% sequence identity between their 
MD-2 or TLR4 proteins, better enabling direct comparison of these structures (102).  However, 
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as mentioned in our prior discussion of LPS and lipid IVa, there are species differences 
stemming from the recognition of lipid IVa which serves as a weak agonist in mice and an 
antagonist in humans (11-13).  All of the crystal structures with the tetraacylated ligands Eritoran 
and lipid IVa show that the ligand acyl chains are completely sequestered in the pocket of MD-2 
(95).  However, in the pocket of human MD-2, the antagonists Eritoran and lipid IVa are rotated 
by 180 degrees relative to the binding position of agonistic E. coli LPS (77, 102).  Intriguingly, 
this rotation of lipid IVa does not occur in mouse MD-2 (77, 103), but additional structures need 
to be solved to confirm whether this rotation event is characteristic of all tetra-acylated inhibitory 
molecules. 
The size of the MD-2 pocket does not increase upon binding hexaacylated LPS.  Instead, 
one additional acyl chain of LPS is accommodated completely inside the pocket of both mouse 
and human MD-2 by displacing the backbone and phosphate residues of LPS out of the pocket 
and shifting the MD-2 loop containing phenylalanine 126 (F126 loop) by ~5Å, when compared 
to its position in the structures of human MD-2 bound to Eritoran or lipid IVa (103).  Typically, 
MD-2 utilizes charged amino acid residues present just inside the cavity of MD-2 or located in 
the adjacent TLR4 of the 1:1 TLR4/MD-2 dimer to orient and stabilize the phosphates of 
tetraacylated Eritoran and lipid IVa, as described previously (77, 95, 99, 103).  However, due to 
the accommodation of the additional acyl chains in LPS, the newly exposed negatively charged 
phosphates of LPS are now able to interact with the positively charged residues of the opposing 
TLR4 monomer of the 2:2 TLR4/MD-2 dimer.  Importantly, the sixth acyl chain of LPS is 
partially omitted from the MD-2 pocket and, together with the displaced F126 loop of MD-2, 
provides a new surface capable of binding the opposing TLR4 monomer to form the functional 
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TLR4/MD-2 signaling complex (Figures 1.3A through 1.3C).  This structural configuration of 
TLR4/MD-2 underlies the molecular basis of the strong agonist activity of LPS (77, 103). 
 
1.6 Dermatophagoides pteronyssinus allergen (Der p 2) 
 An additional project described in Chapter 4 of this thesis focuses on a structural 
homologue of MD-2 called Der p 2.  Der p 2 is a 15 kD allergen that is found in the gut, 
excretory system, and fecal matter of the European house dust mite Dermatophagoides 
pteronyssinus (105, 106).  House dust mites are a major source of indoor aeroallergenic proteins 
(107) and mite extracts contain LPS (1.05 ng LPS/mg extract) (108).  Although the geographical 
localization of dust mites differ with changes in humidity, Dermatophagoides pteronyssinus 
mites are found in every continent (109).  Der p 2 was named following allergen naming 
conventions determined by the World Health Organization and International Union of 
Immunological Societies (WHO/IUIS).  “Der” indicates the first three letters of the genus of 
origin, “p” indicates the first letter of the species of origin, and the Roman numeral “2” to 
indicates the order of purification.  There are 15 different natural sequence variants of Der p 2, 
each designated by four digits.  Allergenic proteins have been divided into 19 different groups 
based on structural homology with group members.  Der p 2 is a member of the group 2 
allergens, and additional group members are listed by the WHO/IUIS in a searchable database, 
available at http://www.allergen.org/ (110).   The 146 amino acid sequence of Der p 2 revealed 
both a 17 amino acid N-terminal secretion signal and less than 16% sequence identity with MD-2 
(111).  However, other group 2 allergens have highly homologous sequences to Der p 2.  For 
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example, Der f 2, a group 2 allergen produced by the American dust mite Dermatophagoides 
farinae, shares 87% sequence identity with Der p 2 (112). 
 Der p 2 and other aeroallergens are processed by antigen presenting cells and displayed 
for T cell recognition (Figure 1.4A).  In individuals who are predisposed to an allergic response, 
these epitopes stimulate helper T cells (TH2 cells) to produce cytokines like IL-4 which activate B 
cells to generate IgE antibodies (113).  These antigen-specific IgE antibodies bind their high 
affinity receptor (FcεRI), which is primarily expressed on the surface of mast cells and basophils.  
Upon re-exposure to and binding of the allergen, the FcεRI receptors of mast cells and basophils 
are crosslinked and allergy induced signaling is activated.  Activation causes release of allergen 
mediators, including granules of histamine, and many downstream signaling effects, including 
the production of cytokines IL-4, IL-13, and IL-5, which enable the recruitment and activation of 
additional immune cells, like helper TH2 cells, macrophages, and eosinophils.  Histamine, 
cytokines, and other mediators released during the allergy-induced activation of these innate and 
adaptive immune cells cause inflammation, smooth muscle cell induced airway constriction, and 
formation of goblet cells producing large amounts of mucus, resulting in allergy symptoms.  
Prolonged allergic response leads to chronic airway restriction and inflammation characteristic of 
the most common form of asthma in the United States, which is called allergic asthma (114).  
More than 80% of asthma suffers have detectable levels of IgE antibodies to Der p 2 (115).    
 To test the structural, functional, and allergenic properties of Der p 2, the allergen has 
been purified from dust mite excrement and homogenate, as well as expressed as a recombinant, 
soluble protein in many cell lines and in the yeast S. cerevisiae (116) and P. pastoris (117).  Both 
the NMR (1AV9) (118) and 2.15 Å x-ray crystal structures (1KTJ) (119) of Der p 2 have been 
determined.  As mentioned previously, the x-ray structure of Der p 2 is highly similar to MD-2 
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(Figure 1.4B), highlighted by the fact the structure of Der p 2 was used to generate an early 
molecular model of the structure of MD-2 (120).  Much like MD-2, Der p 2 contains an 
immunoglobulin-like fold with three beta strands in the first beta sheet and five beta strands in 
the second beta sheet.  Unlike MD-2, Der p 2 contains only six cysteines, which are all 
coordinated in three disulfide bonds leading to greater ease of purification than MD-2.  Unlike 
other allergenic proteins produced by D. pteronyssinus, Der p 2 is highly thermostable and is 
able to accommodate temperatures in excess of 100oC without denaturation (121). 
 Because of the structural similarity between Der p 2 and MD-2, many pondered the 
presence of functional homology.  Recent work by Trompette and colleagues has shown that Der 
p 2 is able to functionally replace MD-2 in mediating LPS signaling through TLR4 (122).  First, 
purified Der p 2 was capable of stimulating production of IL-8 in TLR4 positive HEK293 cells 
that lacked MD-2 (122).  To indirectly show that IL-8 production was due to the ability of Der p 
2 to interact with TLR4, an alanine mutant of Der p 2 in tyrosine 91 was made.  Der p 2 Y91 is 
homologous to Y102, a conserved residue in MD-2.  As mentioned during our discussion of the 
structure of MD-2 in this chapter, mutation of Y102A in MD-2 resulted in loss of TLR4 binding.  
Likewise, mutation of Der p 2 Y91A resulted in a reduction of IL-8.  Further, addition of LPS 
and Der p 2 to HEK 293 cells containing both MD-2 and TLR4 promoted increased production 
of IL-8 compared to LPS stimulation of HEK 293 cells with MD-2 and TLR4 alone, suggesting 
Der p 2 may contain an LPS delivery ability and may interact TLR4 and the MD-2/TLR4 induce 
pro-inflammatory signaling (122).  Thus, Der p 2 is suspected to be a potent allergen by binding 
and delivering LPS to TLR4, without a requirement for MD-2.   
In support of the functional studies, biochemical evidence shows HA-tagged Der p co-
immunoprecipitates with biotinylated E. coli LPS (122).  Both Der p 2 NMR and x-ray crystal 
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structures showed two regions of additional electron density between the two beta sheets, which 
in the x-ray structure was shown to accommodate 14 to 16 carbon chains.  The authors indicated 
this may serve as a binding site for the hydrophobic fatty acid tails of LPS, but noted the beta 
sheets would need to open, like a clamshell, in order to more fully accommodate the ligand (118, 
119).  Additional LPS binding data is limited for Der p 2, but the homologous group 2 allergen 
Der f 2 possesses a similar clamshell cavity in the x-ray crystal structure (123).  An assay 
measuring the intrinsic fluorescence of the only tryptophan present in MD-2 (W23), Der p 2 
(W109), and Der f 2 (W109), has been used to measure LPS binding interactions.  In all three 
structures, this tryptophan residue is located near the entrance of the potential clamshell LPS 
binding pocket with its side chain oriented into the pocket.  When each protein was mixed with 
E. coli 0111:B4 LPS, it resulted in decreased fluorescence and measurable dissociation constants 
for MD-2 (65 x 10-9 M) and Der f 2 (6 x 10-8 M) (124), but Der p 2 had no detectible reduction of 
fluorescence (125).  NMR analysis of radiolabeled E. coli LPS isolated with Der f 2 revealed 
chemical shifts suggestive of a bound glycolipid (124).  Moreover, cross-linking studies revealed 
a novel band at 32 kD, which Ichikawa and colleagues noted may correspond to Der f 2 cross-
linked with LPS (124).  Finally, Der f 2 lysine residues and additional amino acids present in the 
hydrophobic clamshell cavity had detectable NMR chemical shifts upon LPS binding (124). 
 Data also shows Der p 2 may interact with TLR4.  Co-immunoprecipitation studies in the 
work of Trompette and colleagues showed HA-tagged Der p 2 bound to both Flag-tagged MD-2 
and, to a lesser extent, YFP-tagged TLR4.  HA-tagged Der p 2 also co-immunoprecipitated with 
the HA-tagged MD-2/YFP-tagged TLR4 complex.  Further, Flag-tagged CD14 also co-
immunoprecipitated with HA-tagged Der p 2, suggesting Der p 2 may be able to accept LPS 
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from CD14 (122).  However, the biophysical conformation of interactions and the molecular 
basis for interactions between Der p 2 and TLR4, MD-2 and CD14 have not been determined.   
 Experimental evidence indicates Der p 2 may play more than one role in the induction of 
allergy.  For example, challenge of wild type mice with recombinant Der p 2 and picogram levels 
of LPS resulted in helper T cell (TH2 cell) stimulated inflammation and increased plasma IgE 
levels.  Since the same amount of recombinant Der p 2 in TLR4-deficient mice did not induce 
either inflammation, increased IgE levels, or an allergic response, TLR4 is required (122).  Most 
importantly, Trompette and colleagues were able to reconstitute cell infiltration and lung section 
staining typical of an allergic asthma mouse model in MD-2 deficient mice by treatment with 
Der p 2 (122).  Similarly, Der f 2 has been shown to activate downstream TLR4 signaling in 
alveolar macrophages, including stimulation of NF-ĸB (126).  Thus, the ability of Der p 2 and 
other homologous class 2 allergens to mimic the molecular interactions of MD-2 could be one 
reason why these proteins are such potent aeroallergens.  Thus, not only is Der p 2 the antigenic 
target of the adaptive immune system in allergic patients, but Der p 2 also appears to act as an 
adjuvant to the allergic response by stimulating inflammation and adaptive immune activation 
through the TLR4 LPS sensing complex of the innate immune system. 
 In Chapter 4, we describe our efforts to better understand the molecular interactions 
between Der p 2 and LPS sensing complex components.  We used yeast display technology to 
create stable, full-length construct of Der p 2 on the surface of S. cerevisiae yeast through N and 
C-terminal fusions with the a-agglutinin adhesion subunit, Aga2.  We tested the ability of our 
Der p 2 Aga2 fusions to associate with anti-Der p 2 antibodies, E. coli LPS, and purified human 
TLR4.  Although we had limited success in identifying binding of N and C-terminal Aga2 
fusions of Der p 2 to LPS, we were unable to reliably detect TLR4 binding to Der p 2.  As 
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controls, we were able to detect E. coli LPS and TLR4 binding to N and C-terminal Aga2 fusions 
of MD-2.  We decided to use our established Der p 2 yeast display system to determine if we 
could detect anti-Der p 2 IgE in the serum of atopic patients.  We screened allergic and non-
allergic human serum and plasma samples for IgE binding by flow cytometry.  As described in 
Chapter 4, we created binding profiles via titration and compared the sensitivity of our detection 
of IgE binding to yeast displayed N and C-terminal Aga2 fusions of Der p 2 with international 
unit measurements from the ImmunoCAP system.  These results show that a common flow 
cytometer, instead of an expensive proprietary detection system, can be used to reliably detect 
IgE from dust mite allergic serum and plasma patient samples. 
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Figure 1.1:  Central pathway of LPS sensing 
 
Lipopolysaccharide (LPS; red and white) from the outer membrane of Gram negative bacteria is 
shuttled by lipopolysaccharide binding protein (LBP; green) to soluble CD14 [(sCD14-LPS)2; 
blue] or membrane CD14 (mCD14-LPS; blue).  Soluble CD14 is depicted as a dimer, but our 
human CD14 is functional as a monomer.  Either form of CD14 shuttles LPS to the MD-2 pocket 
of the Toll-like receptor 4 signaling complex (LPS-MD-2-TLR4)2, which induces signaling upon 
dimerization induced by LPS binding to MD-2.  Reprinted with permission from Elsevier: Peri, 
F. and M. Piazza. (2012). Therapeutic targeting of innate immunity with Toll-like receptor 4 
(TLR4) antagonists. Biotechnol. Adv. 301 (1): 251-260 (Figure 1). 
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Figure 1.2:  Lipopolysaccharide (LPS) 
(A), Chemical structure of lipopolysaccharide (LPS) from E. coli, described in detail in this 
Chapter.  (B), Chemical structure of tetraacylated biosynthetic precursor for lipid A (lipid IVa) 
from E. coli, described in detail in this Chapter. 
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Figure 1.3:  Ligand Binding by Human MD-2 and TLR4 
 
(A), The Ra chemotype of E. coli LPS (red) bound to human MD-2 (3FXI.pdb) causes a shift in 
the position of the loop containing F126, which enables dimerization with the opposing TLR4.  
(B), The synthetic inhibitor Eritoran (yellow) does not rotate in the pocket relative to the position 
of E. coli LPS and does not induce a shift of the F126 loop, leaving the loop solvent exposed. 
(C),  Similar to Eritoran, the E. coli LPS biosynthetic precursor, lipid IVa, does not rotate in the 
pocket relative to the position of E. coli LPS and does not induce a shift of the F126 containing 
loop, leaving the loop solvent exposed. (D), Upon LPS binding, receptor dimerization occurs 
creating an M-shaped dimer capable of activating signaling.  Adapted and reprinted with 
permission from authors: Manavalan, B., Basith, S., and S. Choi. (2011). “Similar structures but 
different roles-an updated perspective on TLR structures.” Front. Physiol. 2: 41., Figure 4. 
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Figure 1.4:  Allergic response and Der p 2 
 
(A), Immune recognition of allergen induces allergic asthma.  Lung dendritic cells (lime) take up 
allergen, such as Der p 2, (orange) and migrate to the lymph node, where they digest and display 
epitopes using major histocompatibility complex II (MHC-II) for recognition by the T-cell 
receptor (TCR) of TH2 T-cells (blue).  TH2 cells stimulate B-cells (purple) to become long-lived 
IgE producing plasma cells.  IgE binds its receptor (FcεRI) on the surface of mast cells (orange).  
Upon re-exposure and allergen induced crosslinking of FcεRI receptors, release of histamine and 
other mediators occurs from mast cell degranulation, as well as recruitment of TH2 effector cells 
to the airway, capable of producing chemokines including IL-4, IL-13, and IL-5, which activate 
airway narrowing, mucus production, and eosinophil degranulation characteristic of allergic 
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asthma.  Along the way, the allergen Der p 2 may be capable of inducing pro-inflammatory 
signaling through molecular mimicry of MD-2 expressed in these cells with Toll-like receptor 4 
(not shown).  Adapted and reprinted with permissions from: Holtzman, M. J. (2012). Asthma as 
a chronic disease of the innate and adaptive immune systems responding to viruses and allergens. 
J Clin Invest. 122 (8): 2741–2748.  (B), MD-2 (cyan) and Der p 2 (blue) are structurally similar.  
The position of disulfide bonds are indicated (yellow).  Mutation of Tyr 91 was shown 
previously to disrupt the ability of Der p 2 to induce MD-2/TLR4 responses (122).  In Der p 2, 
A115 (pink) is in a synonymous position with F126 in MD-2 (green), which lies in the loop that 
shifts position upon agonist binding to create a new surface for interaction with TLR4 in the 
TLR4 LPS signaling complex. 
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CHAPTER 2: 
 
X-ray Crystallography of Human CD141 
 
2.1 Introduction 
 
CD14 plays a central role in the LPS signaling cascade by acting catalytically in concert 
with LBP to deliver Gram-negative bacterial lipopolysaccharide to MD-2/TLR4, increasing the 
sensitivity of the immune system to the presence of low levels of LPS (28, 30, 35, 40, 41).  LPS 
binding to MD-2/TLR4 enhances receptor dimerization, forming a new dimeric TIR interface for 
signaling adaptor molecules that are capable of propagating pro-inflammatory signaling in an 
effort to clear infection.  As discussed in Chapter 1, widespread infection and activation of pro-
inflammatory signaling can cause fatality through sepsis (65, 66) and murine CD14 deficiency 
reduced pro-inflammatory cytokine production and protected mice in septic shock models from 
lethal doses of LPS (67).  Determining the crystal structure of CD14 is an important step to 
empower pharmaceutical intervention of CD14 function during sepsis. 
The molecular interactions involved in the binding and delivery of structurally diverse 
ligands including LPS presumably requires multiple protein-ligand and protein-protein 
interaction sites on CD14 that are currently undefined.  Additionally, the mechanisms involved 
in delivery of these ligands to multiple Toll-like receptor complexes are also unresolved.  To 
address this gap in knowledge, many groups have purified various recombinant forms of soluble 
CD14 using bacteria, yeast, insect, and human cellular expression systems (30, 127-137), often 
with the goal of structure determination (135, 136).  Currently, only the unliganded crystal 
                                                          
1 Reprinted in part, with permission, from Kelley, S. L., Lukk, Tiit, Nair, S. K., and R. I. Tapping. (2013). “The 
crystal structure of human soluble CD14 reveals a bent solenoid with a hydrophobic amino-terminal pocket.” J. 
Immunol. 190 (3): 1304-1311. 
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structure of mouse CD14, purified from SF9 insect cells, has been solved (69).  Mouse CD14 
possesses an N-terminal hydrophobic cavity that provides a putative binding site for LPS and 
other acylated ligands.  Despite previous efforts, no structure of human CD14 has been 
determined and the structural similarity between mouse and human CD14 is unresolved.  We 
report the crystal structure of human CD14 (4GLP.pdb).  Since sepsis is the most common cause 
of death in US intensive care units (138), information garnered from the structure of human 
CD14 may foster ligand binding structural studies or drug development efforts. 
 
2.2 Materials and Methods 
 
2.2.1 Reagents 
 Unless otherwise indicated, reagents and chemicals were purchased from Sigma-Aldrich.  
DNA polymerases Taq, Platinum Taq, and Platinum Pfx, and bacteriophage T4 DNA ligase were 
purchased from Invitrogen Life Technologies (Invitrogen).  QIAquick Gel Extraction, QIAprep 
Spin Plasmid Miniprep, HiSpeed Plasmid Midi and Maxiprep, and QIAquick PCR Purification 
kits were purchased from Qiagen.  Chemically competent E. coli DH5α cells and LB-agar plates 
containing 100 g/mL ampicillin were purchased from the University of Illinois at Urbana-
Champaign (UIUC) cell Media Facility (kindly produced by Dr. Sandra McMasters).  LB media 
was produced by mixing 10g tryptone (VWR, Cat. No. 90000-286), 5g yeast extract (Fisher, Cat. 
No. df0127179) and 10 g NaCl in 1L total volume of water prior to autoclaving.  LB-Amp was a 
mixture of LB media and 100 g/mL ampicillin sodium salt (Sigma-Aldrich, Cat. No. A9518).  
6xDNA loading dye was prepared by mixing 10 mM Tris HCl, pH 7.6, 0.03% bromophenol 
blue, 0.03% xylene cyanol FF, 60% glycerol, and 60 mM EDTA.  5xSDS-PAGE reducing 
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loading dye was prepared by mixing 250 mM Tris-HCl, pH 6.8, 10% SDS, and 30% glycerol 
with 10% -mercaptoethanol (-me) or 1 M dithiothreitol (DTT).  Polyclonal Goat Anti-Human 
CD14 and two Mouse IgG1 Anti-Human CD14 monoclonal antibodies (63D3 and 28C5) were 
kindly provided by Dr. Peter Tobias, The Scripps Research Institute, La Jolla, CA (139). 
 
2.2.2 Cloning and Site Directed Mutagenesis 
 Two constructs with sequence similarity named HsCD14 and HLCD14 (Figure 2.1) were 
created for structural studies.  Both constructs share a sense primer containing an EcoRI site, 
Kozak sequence for enhancing eukaryotic ribosome recognition during translation initiation 
(140), and a portion of the N-terminal secretion signal of human CD14 beginning at aa 1, which 
is removed during protein expression.  Additionally, two antisense primers were designed to 
contain varied portions of the C-terminal coding region of human CD14, in addition to a XbaI 
cleavage site and thrombin digestion site (LVPRGS) (Figure 2.2A).  Primer sets for the HsCD14 
construct (aa 1-337) and HLCD14 construct (1-367) were utilized to amplify CD14 encoding 
human genomic DNA (kindly provided by a former Tapping lab member, Dr. Katherine Omueti) 
using a GeneAmp PCR System 9700 thermocycler (Applied Biosystems) according to the 
polymerase manufacturer’s instructions (Invitrogen) for polymerase chain reaction (PCR) and 
standard molecular biology techniques (141).   
 Both PCR products and a modified pDisplay cloning vector (Figure 2.2B), a kind gift 
from Dr. David Kranz, University of Illinois, Urbana-Champaign, were digested with EcoRI, 
XbaI and NheI restriction enzymes (New England Biolabs) and separated by agarose gel 
electrophoresis run alongside a 1kB DNA ladder (Promega) with 6xDNA loading dye on a 1% 
agarose gel.  Calculated base pair (bp) sizes (Biology Workbench) visualized for products in 
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each reaction are undigested pDisplay vector (6,154 bp), EcoRI and NheI digested pDisplay 
vector (5,542 bp & 612 bp), EcoRI and XbaI digested HLCD14 PCR product (1,081 bp), and 
EcoRI and XbaI digested HsCD14 PCR product (991 bp).  Following digestion, inserts and 
vector were ligated using the manufacturer’s protocol for T4 DNA ligase (Invitrogen).   
 Site directed mutagenesis of the HsCD14 construct to create a cysteine to serine point 
mutation (C306S) was completed by primer extension (Figure 2.2C) on a GeneAmp PCR 
System 9700 thermocycler (Applied Biosystems).  The HsCD14 C306S mutation was confirmed 
via two methods.  First, the loss of a PvuII digestion site (5’-CAG^CTG-3’) generated by one 
nucleotide change (underlined) upon mutagenesis to serine (5’-CAGCAG-3’).  Upon 1% agarose 
gel electrophoresis of PvuII digested DNA encoding HsCD14 isolated by miniprep (Qiagen) 
from heat-shock transformed E. coli DH5α colonies, identification of select colonies containing 
the C306S mutation (#1 and #3) was conducted visually by locating two resulting bands (5,542 
bp & 612 bp) instead of three resulting bands (3,418 bp, 3,172 bp, & 612 bp) (Figure 2.2D).  
Second, DNA sequencing (UIUC Biotechnology Center) confirmed the single nucleotide 
thymine to adenine expected result in the HsCD14 serine mutant (Figure 2.2E).   
Additionally, pDisplay vectors containing DNA from both HLCD14 and HsCD14 were 
also transformed into E. coli DH5α cells heat-shock (Invitrogen).  Positive clones were selected 
by ampicillin resistance on LB-Ampicillin agar plates.  After overnight growth in the 37oC warm 
room, single colonies were picked and grown in 3 mL LB-Amp media in 15 mL polystyrene BD 
FalconTM round bottom tubes (BD Biosciences) in a 37oC incubator with shaking overnight.  
Successful transformation of E. coli DH5α colonies was confirmed using Qiagen DNA 
extraction and restriction enzyme digestion with EcoRI and NheI, followed by 1% agarose gel 
electrophoresis to visualize the sizing of HLCD14 and HsCD14 inserts.  The nucleotide 
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sequences of both constructs were confirmed by capillary electrophoresis DNA sequencing using 
the ABI 3730 Genetic Analyzer and Data Collection software Version 3.0 (UIUC Biotechnology 
Center).    
 
2.2.3 Expression and Stable Cell Line Selection 
After utilizing E. coli DH5α cells to amplify the vector, DNA was extracted with the 
QIAprep spin miniprep, followed by ethanol precipitation and QIAquick purification.  Human 
embryonic kidney cells (HEK 293F) from Invitrogen Life Technologies (FreeStyle 293-F, Cat. 
No. R790-07) were cultured, transfected with HLCD14 or HsCD14 containing modified 
pDisplay vector, and stably selected using previously described methods (83).  Unless otherwise 
stated, HEK 293F cells were cultured in a humidified incubator at 37oC with 8% CO2.  The 
transfection reagent 293fectinTM (Invitrogen) utilized the cationic lipid transfection method (142) 
to envelope CD14 containing pDisplay vector and transfer it into 1mL of 3 x 107 cells/mL HEK 
293F cells grown adherent in 24 well plates (TPP tissue culture plates, 24 well, flat bottom, 
polystyrene; Cat. No. Z707791) with serum-free FreeStyle 293 expression medium (Invitrogen; 
Cat. No. 12338-018).  Following transfection, cells were placed in 96 well plates (TPP tissue 
culture plates, 96 well, flat bottom, polystyrene; Cat. No. 92696) in quantities varied by limiting 
dilution.   Adherent, stably expressing HEK293F CD14 transfectants were selected by neomycin 
resistance by passaging cells for one month in serum-free media containing 0.25 mg/mL G418 
sulfate (Gemini BioProducts, Cat. No. #400-111P) stabilized with a 1:1 mixture of culture 
supernatant from HEK 293F cells transfected with pDisplay vector alone.  Protein expression 
levels were qualitatively measured and selection for higher expressing transfected HEK 293F 
cells was conducted by a 10% Tris-HCl sodium dodecyl sulfate polyacrylamide gel (10% SDS-
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PAGE) separation followed by Western blotting with a polyclonal anti-CD14 antibody (data not 
shown). 
 
2.2.4 Purification 
Both proteins were purified using a four-step chromatographic procedure with slight 
variations.  First, protein G affinity purification, modified from previously published methods 
(83), was used to harvest the Fc-fusion (HLCD14-Fc or HsCD14-Fc) of both constructs from 
two liters of HEK 293F culture supernatant seven days following seeding to 0.3 x 106 cells/mL 
in serum-free Freestyle 293F media with G418 (0.25 mg/mL) (Figures 2.3A and 2.4A).  
Recombinant Protein G sepharose beads (GE Healthcare; 2 mL 50% slurry) were added to the 
filtered supernatant with stirring overnight at 4oC.  Protein G beads bound to CD14-Fc were 
harvested by centrifugation at 2,500 x g, 15 min, 4oC and packed into a disposable PD-10 
column (GE Healthcare).  The column was washed with 0.02 M sodium phosphate, pH 7.0 and 
eluted in 1 mL fractions for ten column volumes of 0.1 M glycine-Cl, pH 2.3 with 1 mL 
neutralizing 1 M Tris-HCl, pH 9 buffer.  A Precision PlusTM Dual Color molecular weight 
marker (Bio-Rad) was used to qualitatively size protein in each elution fraction (5 L), which 
was loaded with 5xSDS-PAGE reducing loading dye on a 10% SDS-PAGE (143) for 
electrophoresis under reducing conditions.  SDS-PAGE gels were subsequently stained with 
Coomassie Brilliant Blue R-250, 40% methanol, and 14% acetic acid (stain solution) overnight 
with rotation at room temperature, and destained with 40% methanol and 10% acetic acid 
(destain solution) in iterative 20 minute incubations at room temperature.  Original SDS-PAGE 
gels were preserved using hydrated cellophane in a Tut’s Tomb gel tray (Idea Scientific).  A 
Western blot using anti-human CD14 polyclonal antibody confirmed Protein G elution fractions 
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1-5 contained HLCD14-Fc protein (Figure 2.3B).  Similar Western blot analysis was completed 
for HsCD14-Fc following Protein G (data not shown).   
At this stage, the purification procedure varied between constructs.  Thrombin (Novagen) 
was added to HLCD14-Fc fusion protein in an effort to remove Fc by overnight incubation at 
22oC visualized by 10% SDS-PAGE with Coomassie Brilliant Blue R-250 staining (Figure 
2.3C).  Additional effort to improve cleavage efficiency included the addition of 0.01% SDS 
during thrombin digestion (data not shown) to no avail.  HLCD14-Fc thrombin digestion 
reactions were purified through an ÄKTAprime™ plus FPLC (GE Healthcare) fitted with two 
1mL Hi-Trap Protein A high performance columns (GE Healthcare) run in tandem at a flow rate 
of 1ml min-1 in 0.02 M Tris HCl, pH 8.5 buffer.  Fractions were visualized by 10% SDS-PAGE 
with Coomassie staining (Figure 2.3D).  Due to incomplete isolation of thrombin cleaved 
HLCD14 by Protein A affinity purification, pooled Protein A fractions containing HLCD14 were 
further purified on two 5 mL Hi-Trap Q (GE Healthcare) anion exchange columns run in tandem 
at 4oC by injection via a 10 mL loop and elution using linear NaCl gradient (0.02 M - 1 M) in 
0.02 M Tris-HCl, pH 8.5 and a 1 mL/min flow rate.  Fractions were visualized by 10% SDS-
PAGE with Coomassie staining correspond to the Hi-Trap Q elution profile (Figure 2.3E).   
Human soluble CD14 (HsCD14 C306S) protein was similarly digested with thrombin 
overnight in the absence of 0.01% SDS.  Products of the reaction were separated by injection of 
the reaction into ÄKTAprime™ plus FPLC fitted with two tandem 1mL Hi-Trap Protein A high 
performance columns (GE Healthcare) run at a 1ml min-1 flow rate in 0.02 M Tris HCl, pH 8.5.  
The flow through fractions were collected and re-injected into the FPLC on two tandem Protein 
A columns three times consecutively to remove additional Fc.  Flow through fractions containing 
soluble HsCD14 were identified by 10% SDS-PAGE stained with Coomassie, pooled, and 
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concentrated to 1mL using an Amicon Ultra-15 unit (Millipore).  Next, pooled HsCD14 was 
injected into two 5 mL Hi-Trap Q anion exchange columns (GE Healthcare) run in tandem with 
a linear NaCl gradient (0.02 M - 1 M) in 0.02 M Tris-HCl, pH 8.5 at 4oC using a 1 mL min-1 
flow rate to further purify HsCD14 protein.  CD14 containing fractions, as analyzed by 10% 
SDS-PAGE stained with Coomassie, were concentrated using an Amicon Ultra-15 unit 
(Millipore) to 0.5 mL.  Finally, pooled HsCD14 was injected for size-exclusion chromatography 
using a Superdex 200 column (GE Healthcare) equilibrated with 0.02 M Tris-HCl, pH 8.5 and 
0.1 M NaCl at a flow rate of 0.4 mL min-1.  Fractions containing HsCD14 were analyzed by 10% 
SDS-PAGE stained with Coomassie, pooled, and concentrated to 10 mg ml-1 using an Amicon 
Ultra-4 unit (Millipore) as measured by Pierce BCA assay (Rockford, IL).  This four column 
purification process yielded ~2 mg L-1 soluble, human CD14 with >90% purity ascertained 
visually by 10% SDS-PAGE gel stained with Coomassie (Figure 2.4A) corresponding to the 
Superdex 200 elution profile (Figure 2.4B).    
 
2.2.5 Initial Crystallization Screening 
Human CD14 (HsCD14 C306S) was crystallized using the hanging drop vapor diffusion 
method.  Crystallization conditions were initially screened using commercially available sparse 
matrix kit conditions including Hampton Research Crystal Screens I and II, Emerald Biosystems 
Wizard I and II, Hampton Research Natrix, and Hampton Research Salt Reaction, as well as a 
handmade crystal screen targeting the previously published mouse CD14 crystallization 
condition (1 l protein solution and 1 l of crystallization buffer containing 100 mM sodium 
HEPES (pH 7.5), 1.9 M Li2SO4, and 5 mM NiCl2) (69).  Each condition was tested on a 12 mm x 
0.22 mm siliconized glass cover slide (Hampton Research) over a VDX48 plate with sealant 
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(Hampton Research) by mixing 1 l of each screening solution with 1 µl protein solution 
(10 mg ml-1 protein in 0.02 M Tris-HCl, pH 8.5 and 0.1 M NaCl) equilibrated against 300 µl 
screening solution in the reservoir.  Sparse matrix screening in hanging drop vaporization trays at 
22oC, 18oC, and 4oC lead to three conditions with single crystals (Figure 2.5):  Emerald 
Biosystems Wizard I #28 (20% PEG 3,000, 0.1 M HEPES, pH 7.5, and 0.2 M NaCl) after 2 - 4 
days at 22oC; Hampton Research Crystal Screen I #18 (20% PEG 8,000, 0.1 M Na cacodylate, 
pH 6.5, and 0.2 M Mg(OAc)) after 6 days at 18oC; and Emerald Biosystems Wizard II #28 (20% 
PEG 8,000, 0.1 M MES, pH 6.0, and 0.2 M Ca(OAc)2) after 3 weeks at 22
oC (144-146).  The 
best initial diffraction resolution (6.2 Å) was obtained using Emerald Biosystems Wizard II #28 
(Figure 2.6).  
  
2.2.6 Crystallization Optimization 
Extensive work was conducted to improve diffraction resolution from 6.2 Å.  Improved 
purification buffer conditions were identified using a solubility screen (147).  A PEG 6,000 
sparse matrix screen (Hampton Research) and handmade crystallization buffers were prepared 
varying salt, precipitant, and buffer concentrations nearby the initial crystallization conditions, 
leading to an optimized hit at K#19 with 4.02 Å resolution (Figure 2.7).  Additionally, 1 l of 
each initial crystallization solution and 1 µl protein solution (10 mg ml-1 protein in 0.02 M Tris-
HCl, pH 8.5 and 0.1 M NaCl) was combined with 0.1 l of either 96 distinct Additive Screen 
reagents (Hampton Research), 96 distinct detergents from Detergent Screens 1-3 (Hampton 
Research), 96 additives in Silver Bullets (Hampton Research) and Heavy Atom screens 
(Hampton Research).  Alternatively, in a 3 l hanging drop, 1.5 l protein and 0.9 l well 
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solution was mixed with 0.6 l additives to test the effects of adding a 5 fold dilution of 
Hampton Research additives, detergents, and Silver Bullet reagents. 
In vitro proteolytic screening was also conducted through the addition of various 
dilutions (10-100 fold) of stock solutions of commercially available proteases (Sigma) including 
chymotrypsin (1 mg/mL), trypsin (1.5 mg/mL), Glu C V8 (2.0 mg/mL), subtilisin A (1.0 
mg/mL), thermolysin (1.0 mg/mL), and elastase (1.0 mg/mL) to 30 g purified HsCD14 protein 
in 5 L reaction volume for 30 and 100 minutes at room temperature prior to the addition of 
loading dye and visualization by 10% SDS-PAGE (data not shown) (148, 149).  PeptideCutter 
(ExPASy; available at http://web.expasy.org/peptide_cutter/) predicted the following number of 
cleavage sites for each protease: chymotrypsin (15), trypsin (30), Glu C (34), elastase (74), and 
thermolysin (123).  A 10 fold dilution of each protease was also added directly to the hanging 
drop of the 6.2Å condition to screen proteolysis in situ.   
Surface lysine residues were reductively methylated using dimethylamine-borane 
complex using the manufacturer’s protocol (Sigma) (148, 149).  The methylation reaction 
involved a 2 hour incubation at 277K with gentle mixing of small-gel filtration purified HsCD14 
protein in 50 mM HEPES (pH 7.5) with 250 mM NaCl buffer with 20 uL freshly prepared 1 M 
dimethylamine-borane complex (ABC; Fluka #15584) and 40 uL 1M formaldehyde (Fluka 
33220) per mL solution.  In two hour increments, 20 uL ABC and 40 uL formaldehyde were 
added.  Then, 10 uL of ABC was added and the reaction was incubated overnight at 4oC with 
rotation.  The reaction was quenched with 1M Tris-HCl buffer.  The sample was centrifuged to 
remove any protein precipitant before an additional round of size exclusion chromatography.  
Fractions from the primary elution peak were combined and concentrated to 10 mg/mL and 
MALDI-MS (UIUC Mass Spectrometry Lab) using a sinapinic acid matrix to detect methylation. 
37 
 
Since glycosylation also contributes to protein heterogeneity, we attempted to inhibit 
glycosylation by treating 1 mL cultures of transfected HEK 293F cells with the glycan inhibitors 
Streptomyces tunicamycin (T7765) and benzyl-N-acetyl-a-D-galacotsamide (BAG; B4894) 
(Sigma), screening 12 inhibitor concentrations (0, 0.25, 0.5, 1, 2, 4, 8, 16, 32, 64, 128, and 256 
g/mL).  Additionally, the lowest 0.25 g/mL concentrations of both inhibitors tested were 
added to 30 mL cultures of transfected HEK 293F cells in a separate test for cell viability upon 
treatment (data not shown).  In a second method, N-linked glycans were removed enzymatically 
by incubating HsCD14 for one hour at 37oC in 1xG7 buffer (0.05 M sodium phosphate, pH 7.5) 
containing 1,000 U peptide N-glycosidase F (PNGaseF) (New England Biolabs) prior to Hi-Trap 
Q anion exchange chromatography (GE Healthcare), as described previously in Materials and 
Methods in this Chapter (Figure 2.4C). 
   
2.2.7 Cryoprotection Optimization and Crystal Harvesting 
Cryopreservation reagents were screened using six different crystal handling techniques, 
including:  (a) movement of the crystal to a hanging drop containing cryo, gentle crystal rolling, 
careful harvesting in the loop and freezing (direct transfer); (b) movement of the crystal to 
hanging drops containing decreasing cryo between drops varied by a constant dilution factor, 
with or without crystal ejection from the loop, and freezing (% stepwise); (c) transfer of the 
crystal from the drop to the loop and positioning the loop in a second drop containing the cryo 
solution for 1-30 seconds without crystal ejection from the loop (looped); (d) retention of the 
crystal in the original drop, which was diluted 2 fold with cryo (dilution); (e) movement of the 
crystal to a new hanging drop containing 2.5% glycerol for 30 minutes – 1 week (soaking); and 
(f) plunged directly into liquid nitrogen without cryo preservation solution (no cryo).  Incubation 
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time of the crystal in the hanging drop containing cryo was also varied for the direct transfer and 
% stepwise techniques.  Multiple handmade cryo preservation solutions were tested, with 
stepwise gradients indicated in parenthesis, including:  10-20% 2,3-butanediol (10%), 10-20% 
xylitol (10%), 5-30% trehalose (5%), 5-30% D,L-threitol (5%), 2-30% ethylene glycol (2%), 2-
30% sucrose (2%), 2-30% glucose (2%), 2-30% glycerol (2%), 2-30% MPD (2%), and 2.5-20% 
PEG MW 200, 400, 600, 3350, 4k, 5k, 6k, and 8k (2.5%, 5%, and 10%).  Commercially 
available cryopreservation solutions were also screened, including the Crystal Screen Cryo kit 
(Hampton). 
Using methods described by Heras and Martin (148), crystals were also dehydrated prior 
to vitrification via serial transfer on cover slips exposed to ambient room temperature or on cover 
slips exposed to reservoir for various time points.  Additionally, macromolecular crystal 
annealing after freezing using multiple crystal warming time points and flash annealing after 
freezing in a liquid nitrogen stream was attempted for varied durations (148, 150-152).  Finally, 
room temperature diffraction was conducted at with single crystals harvested on MicroRT 
MiTeGen mounts using manfacturer’s protocols (153).   
Ultimately, single crystals of purified PNGaseF deglycosylated CD14 were grown at 
22oC to a maximum dimension over ~40 days on a 22 mm x 0.22 mm siliconized glass cover 
slide (Hampton Research) over a VDX24 plate with sealant (Hampton Research) by mixing 
1.5 µl 30% PEG 6,000, 0.1 M MES, pH 6.0, and 0.2 M Ca(OAc)2 crystallization solution with 
1.5 µl protein solution (10 mg ml-1 protein in 0.02 M Tris-HCl, pH 8.5 and 0.1 M NaCl) 
equilibrated against 1 mL screening solution in the reservoir (Figure 2.8).  Crystals were 
harvested directly by looping from the drop and plunged immediately into liquid N2 without any 
additional cryoprotection or crystal handling. 
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2.2.8 Data Collection and Structure Determination 
A native diffraction data set including 130 frames at 1o rotation/sec was collected from a 
single vitrified crystal in the optimized 30% PEG 6,000,  0.1 M MES, pH 6.0, and 0.2 M 
Ca(OAc)2 crystallization solution on the LS-CAT beamline, Sector 21 ID-F (Advanced Photon 
Source, Argonne, IL).  Diffraction data were processed to 4.0 Å resolution by a postdoctoral 
student in the Nair Lab, Dr. Tiit Lukk.  Data were indexed and integrated using XDS, followed 
by scaling and merging with XSCALE (154).  The structure solution was determined via 
molecular replacement with Phaser in the CCP4 suite, using the molecular coordinates of mouse 
CD14 (1WWL.pdb), modified with CHAINSAW (155).  Iterative cycles of model fitting were 
completed in COOT, followed by refinement in REFMAC (156).  The final solution of human 
CD14 was deposited (http://www.pdb.org/pdb/search/structidSearch.do?structureId=4GLP) and 
verified with Molprobity in PHENIX (157).  RAMPAGE (University of Cambridge) was used to 
create the Ramachandran plot shown in Figure 2.9.  Data collection and refinement statistics are 
summarized in Table I. 
 
2.3 Results 
 
2.3.1 Generation of Human CD14 for Crystallization 
A number of important parameters were considered in generating a soluble form of 
human CD14 suitable for crystallization.  Since soluble forms of CD14 (aa 20-375, where amino 
acid numbering starts with the first methionine of the unprocessed CD14 protein) are naturally 
heterogeneous at the C-terminus, we generated an expression construct (HLCD14) which 
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contained the naturally occurring N-terminal secretion signal and the majority of the coding 
region of CD14, yet lacked the C-terminal protein sequence required for GPI anchoring.  This 
was done with the knowledge that C-terminal truncation of CD14 does not affect LPS associated 
bioactivity, which resides entirely within the amino-terminal half of the protein (158, 159).   
Additionally, since our shorter construct (HsCD14) is truncated between C306 and C352, which 
are predicted to form the final disulfide bond, we mutated the unpaired C306 residue to serine.  
Both HLCD14 and HsCD14 were expressed as an Fc tagged fusion protein and harvested from 
HEK 293F cell supernatant using protein G sepharose beads.  An engineered thrombin cleavage 
site present in both constructs was utilized for removal of the Fc tag.  However, HLCD14 
showed incomplete cleavage after thrombin digestion (Figure 2.3C); whereas, the Fc fusion was 
more completely removed from HsCD14 upon thrombin digestion.  Thrombin digestion in the 
presence of 0.01% SDS and further purification steps, including protein A affinity 
chromatography and Hi-Trap Q anion exchange chromatography (Figure 2.3D and 2.3E), did 
not increase levels of thrombin digestion or effectively separate HLCD14 from the Fc fusion.  
So, we set HLCD14 aside and redoubled our efforts purifying HsCD14 for structure studies. 
Following thrombin digestion, protein A affinity chromatography and small gel filtration 
of HsCD14 resulted in highly pure, soluble protein suitable for crystallization (Figure 2.4A).  
LPS binding studies and an ELISA based assay measuring production of IL-8 were used to 
determine that our purified protein was bioactive.  These studies will be discussed in detail in 
Chapter 3.  To further ensure improved protein homogeneity for crystallization, we removed 
potentially heterogeneous N-linked glycans using PNGase F.  This enzymatic deglycosylation 
was preferred because mutation of the N-linked glycosylation sites in CD14 prevents cellular 
41 
 
secretion (52).  As observed by others, PNGase F treatment reduced the molecular weight of 
CD14 by approximately 10kD (160, 161) (Figure 2.4C). 
 
2.3.2 Crystal Structure of Human CD14 
Human CD14 crystallized in the trigonal space group  P3221 (Table I).  As listed in 
Table I, five percent of reflections were omitted from refinement and used in the cross-validation 
calculation of the 32.1% R-free value.  A Ramachandran plot was also created for validation, 
showing 8.1% outliers (Figure 2.9).  The crystal structure begins with aa 26, indicating complete 
removal of the leader sequence by HEK 293F cells during secretion along with low electron 
density for the first six amino acids, aa 20-25.  The overall X-ray crystal structure of human 
CD14 reveals a bent solenoid that is formed by 11 leucine rich repeats, each creating a single 
turn (Figure 2.10A).  This is consistent with the leucine rich repeat sequence motifs of human 
CD14 (162), and the expected bent solenoid fold generally characteristic of leucine rich repeat 
containing proteins (163).  The structure also reveals five alpha helices on the convex side, as 
well as eleven beta strands that are coordinated in a parallel beta sheet on the concave side of the 
bent solenoid.  The pairwise proximity between cysteine residues in the crystal structure at 
positions 34 and 51, 187 and  217, as well as 241 and 272 are consistent with the expected 
disulfide bonds of human CD14, which have been shown to be important for proper protein 
folding (135) (Figure 2.11).  Interestingly, recombinant purified human CD14 (HsCD14) lacking 
the C306S mutation, a mutation originally designed to avoid unnatural disulfide binding, did not 
crystallize and formed aggregates in the crystallization drop (data not shown).  
Another key structural feature present in the crystal structure of human CD14 is an N-
terminal pocket or cavity (Figure 2.12A).  Although we cannot know with certainty the position 
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of each side chain at this resolution, the overall cavity of human CD14 is comprised largely of 
hydrophobic residues present in α1 through α5 and 1 through β6 along with their connecting 
loops.  It is reasonable to assume that this hydrophobic pocket serves as the binding site for the 
lipid chains of LPS and other acylated CD14 ligands, especially as the regions making up the 
pocket are entirely contained within the N-terminal region (aa 20-171) of CD14 that has been 
shown to be sufficient for bioactivity (158, 159).  
It is instructive to examine the rim residues of the CD14 hydrophobic pocket as these 
residues likely engage portions of LPS, or other acylated CD14 ligands, that are not 
accommodated by the pocket itself.  Positively charged residues are located in the rim at K71 
and R72 and just outside the rim at R80, K87, and R92 (Figure 2.13A).  Hydrophobic residues at 
W45, F49, V52, F69, Y82, and L89 encircle the rim and their side chains overlay the entrance to 
the pocket.  When measured using the program Chimera (164), the pocket diameter of human 
CD14 from W45 to L89 is 15.7 Å wide.  Interestingly, the hydrophobic pocket entrance is 
subdivided by an interaction between the α1 residue F49 and the α3 residue Y82 (Figure 2.13B).   
 
2.3.3 Comparison of Human and Mouse CD14 Structure 
Human soluble CD14 purifies and crystallizes as a monomer (Figure 2.4A and 2.4B).  In 
contrast, the murine protein crystalized as a dimer with the dimer interface comprised of C-
terminal beta strand interactions (69).  The mouse and human CD14 structures are comparable at 
the C-terminus because both were truncated at similar positions to make them more amenable to 
crystallization (69).  Different crystallization conditions, constructs, and cellular expression 
systems may account for the differences observed in crystal packing between the two proteins.  
Nevertheless, it is unlikely that the C-terminal dimerization of truncated mouse CD14 is 
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biologically relevant (69), as numerous biophysical studies support the idea that bioactive 
soluble CD14 is a monomeric protein (28, 30, 40, 42-45).   
Human and mouse CD14 crystal structures contain a bent solenoid fold and asparagine 
ladder, which are structural features typical of leucine rich repeat proteins (163).  In fact, both 
proteins are highly superimposable with a r.m.s.d. of 1.089 Å (Figure 2.10B).  The secondary 
structure of human CD14 includes alpha helices and beta strands that are equivalent to α1, α4, 
α5, α6, α7, and 3-13 of the published mouse CD14 structure (Figures 2.10B and 2.11) (69).  
Although helical coils exist in human CD14 at locations that are synonymous to helices α2 and 
α3 of mouse CD14, the structure resolution falls just outside the range needed to determine 
helical packing with certainty (Figures 2.10B and 2.11) (165, 166).  Human and mouse CD14 
both contain a large N-terminal hydrophobic pocket consistent with their similar roles in the 
binding and delivery of various lipidated molecules including LPS (Figures 2.12A and 2.12B).  
Similar to human CD14, the main pocket and sub-pockets present in mouse CD14 are comprised 
of hydrophobic residues within α1-5, 1-6, and their connecting loops (69).   Using a structure 
based sequence alignment, created using MultiSeq in VMD (167), we compared the general 
amino acid characteristics present in the residues at the rim of the proposed binding pocket in 
both structures (168).  The authors of the mouse CD14 crystal structure (69) identified 
hydrophilic and hydrophobic amino acids in rim residue positions indicated in blue (Figure 
2.13). Many of these residues, including P39, W41, F45, and Q77 are conserved with rim 
residues at the pocket entrance of human CD14.  Thus, the N-terminal hydrophobic pocket found 
in our crystal structure revealed a conservation of pocket size and hydrophobicity with that of 
mouse CD14. 
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Despite the wide ranging structural similarities between mouse and human CD14, 
differences do exist.  For example, although the amino acids found at equivalent positions of 
mouse and human CD14 generally have similar physical properties, there is variation in the 
charge of certain rim residues.  Namely, the positively charged K38 residue present in the mouse 
protein is not retained in the human protein.  Likewise, the negatively charged D44 residue in 
human CD14 is not found in mouse CD14.  Finally, the diameter and subdivision of the entrance 
to the pocket differs between species.  The mouse crystal structure reveals an 8.0 Å wide 
entrance to the pocket that is bounded on one side by a hydrophobic interaction between F45 and 
F78 (69) (Figures 2.13A and 2.13B).  Residues F45, L49, and I81 in the mouse CD14 structure 
create additional hydrophobic interactions which shield this side of the pocket.  These 
hydrophobic interactions of the mouse CD14 pocket are not present in the human CD14 structure 
whose pocket extends to include the rim residues T85 and L89 (Figures 2.13A and 2.13B).  The 
biological significance of these differences between the pocket and associated rim of mouse and 
human CD14 is difficult to define without structural information from ligand bound proteins.  
 
2.4 Discussion 
 
CD14 sensitizes cells to LPS by delivering this bioactive lipid to MD-2; an essential 
component of the TLR4 signaling complex.  All members of the MD-2 related lipid-recognition 
protein superfamily are characterized by two  sheets organized in an α cup fold to create a 
centralized hydrophobic LPS binding cavity (169).  In the crystal structures of human and mouse 
MD-2 bound to lipid IVa, all four acyl chains of the ligand are buried inside and occupy the 
majority of the hydrophobic pocket volume (99, 103).  Crystal structures of MD-2 in the context 
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of the entire mouse and human TLR4/MD-2/LPS homodimeric signaling complex reveals a 
narrow and deep (1720 Å3 volume) hydrophobic binding pocket that completely sequesters five 
of the six fatty acid chains (77, 170).  The remaining unbound acyl chain lies along the surface of 
MD-2 and, together with the F126 loop of MD-2, creates a new hydrophobic patch that promotes 
homodimer formation by association with TLR4 from an adjacent TLR4/MD-2/LPS complex 
(77, 95). 
Compared to MD-2, CD14 has been reported to afford less protection against enzymatic 
removal of secondary fatty acids of bound LPS (171).  This probably reflects that fact that at 
about 820 Å3, the hydrophobic pockets of both human and mouse CD14 are considerably smaller 
than that of MD-2 (69) (Figures 2.12A and 2.12B).  Similar to MD-2, previous circular 
dichroism, tryptophan fluorescence, and NMR studies suggest that LPS binding does not induce 
large structural changes in human CD14 (136, 172).  Given these volume constraints and pocket 
rigidity, it is unlikely that CD14 can accommodate all the acyl chains of LPS.  This may 
contribute to the reduced affinity of CD14 for LPS compared to MD-2 (43, 44).  
Given the physical limitations of the hydrophobic pocket, we hypothesize that CD14 
stabilizes additional fatty acid chains on a hydrophobic cluster located near α1 just outside of the 
pocket entrance.  A similar hydrophobic cluster is present in a comparable location in the crystal 
structure of mouse CD14 (69) (Figure 2.12B).  In human CD14, the hydrophobic cluster is 
comprised of the amino acids F32, F49, V52, S53, A54, V55, and L89 (Figure 2.12B).  This 
cluster and associated acyl chains of LPS could perhaps create a new protein-protein interaction 
surface that may help facilitate the transfer of LPS to another molecule such as MD-2.  
Our crystal structure confirms that the hydrophobic pocket encompasses the N-terminal 
half (aa 20-171) of CD14 that has been shown to be the bioactive portion of the protein (51).  
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Previous literature strongly supports the hypothesis that LPS binds the pocket.  For example, aa 
26-29 were bound by the anti-CD14 antibody 3C10 neutralizing the ability of CD14 to bind LPS 
or activate cell signaling (173).  Alanine mutagenesis of this same amino acid region resulted in 
the loss of cellular activation (173).  Deletion of human CD14 aa 28-31, 41-44, or 78-82 resulted 
in diminished LPS binding and partial inhibition of bioactivity (174).  Deletion of aa 54-58 
caused loss of LPS binding and abrogated SW620 cellular activation (174, 175).  Human CD14 
aa 57-64 are protected from endoprotease AspN digestion upon binding LPS (172), are bound by 
the anti-CD14 neutralizing antibody MEM18, and their deletion resulted a lack of LPS binding 
and cellular activation functionality (173, 176).  Alanine scanning mutagenesis of the entire N-
terminal region of CD14, encompassing aa 20-171, revealed mutation of aa 28-32 blocks LPS 
binding and mutation of aa 58-63 blocks both LPS binding and cellular activation (51).  Thus, 
extensive deletion mutagenesis, alanine scanning mutagenesis and epitope mapping of inhibitory 
anti-CD14 antibodies have revealed four separate regions (aa 26-32, 41-44, 56-64 and 78-83) in 
the N-terminal half of CD14 that are critical for LPS binding and cell activation (Figure 2.13A).  
We have identified in our crystal structure the location of these four functionally important 
regions near β1, within the loop preceding α1, across β3 and within α3, respectively (51, 173-
176).  The residues in the first three regions near α1, 1 and 3 appear to fulfill critical roles in 
forming the pocket entrance, capping the leucine rich repeat beta sheet, and/or stabilizing proper 
folding of the solenoid.   
Residues in the fourth region encompass a Y82 loop located on the opposite side of the 
pocket entrance.  Although Y82 appears to weakly block the entrance of the pocket through 
interaction with F49, we believe that upon binding LPS, these hydrophobic residues may change 
position to accommodate the acyl chains within the pocket.  Although the corresponding 
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interaction is represented by F45 and F78 in mouse CD14, additional hydrophobic residues 
present in mouse CD14, but absent in human CD14, close off the pocket entrance (Figures 
2.13A and 2.13B).  Overall, our human CD14 crystal structure allows for the resolution of an N-
terminal hydrophobic pocket predicted by multiple studies to be the LPS binding site.  Compared 
to mouse CD14, our work provides an alternative definition of rim residues, reveals an expanded 
pocket entrance, and identifies a unique hydrophobic bridge feature that incorporates residues 
shown to be important in LPS binding and cell activation (Figures 2.13A and 2.13B). 
Hydrophilic residues at the opening of MD-2 have been shown to be important for LPS 
binding by properly aligning the negatively charged 1 and 4’ phosphates of LPS (77, 128).  
Similar to MD-2, charged rim residues in CD14 may be important for orienting or binding LPS.  
For example, previous work has shown that mutation of E47, which falls near the front of the rim 
in α1, to either lysine or arginine can block binding of P. gingivalis LPS (177).  Solution NMR 
spectroscopy analyzing soluble CD14 aa 20-171 bound to the Re chemotype of LPS did not have 
structural assignments available upon publication, but does show high average temperature factor 
evidence for hydrophilic residues at the rim suggesting local flexibility to accommodate LPS 
binding (136).  Further work to develop a ligand bound CD14 structure would help to clarify the 
roles of both the hydrophobic binding pocket and the hydrophilic rim residues required for ligand 
binding. 
A number of natural and synthetic acylated agonists and antagonists are known to be 
shuttled by CD14.  For example, CD14 delivers tri- and di-acylated agonists to complexes 
formed by members of the TLR2 subfamily (56-63, 178).  Natural antagonists of LPS, including 
R. sphaeroides pentacylated lipid A, tetracylated lipid IVa and monophosphoryl lipid A, an 
approved vaccine adjuvant in Europe, are shuttled by CD14 to MD-2/TLR4 (12, 170, 179-181).  
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Eritoran, a synthetic LPS antagonist, that is structurally similar to lipid IVa, is also delivered to 
MD-2 by CD14 (102, 182).  More recently, synthetic LPS inhibitors derived from either 
diacylated sugars or tetraacylated sulfate containing compounds have been identified and shown 
to competitively block LPS binding to CD14 (183-185).  It is highly likely that the hydrophobic 
binding pocket in human CD14 accommodates these natural and synthetic agonists and 
antagonists especially as they contain fewer acyl chains than hexaacylated enteric bacterial LPS 
(180, 186).  Since TLR4 inhibitors are largely LPS mimics that are either delivered by CD14 or 
directly compete with LPS for interaction with CD14, the structural information presented here 
may further the design of drugs for the treatment of sepsis and other inflammatory diseases. 
49 
 
Figure 2.1: Human and Mouse CD14 Sequence Alignment 
 
Sequence alignment using the default parameters of ALIGN (SDSC Biology Workbench; 
available at http://workbench.sdsc.edu) indicating the sequence of two human (HLCD14 & 
HsCD14) and one mouse (MCD14) CD14 construct.  DNA sequencing confirmed our constructs 
agreed with sequences deposited in SwissProt (available at http://www.uniprot.org/) for human 
CD14 (P0857) and mouse CD14 (P10810).  Identical (magenta), conserved (light blue) and 
cysteine (orange) amino acids are highlighted.  Human CD14 and mouse CD14 amino acid 
numbering is indicated above and below the alignment, respectively.  Residues predicted by 
SwissProt to be absent in the mature form of the protein are indicated (gray).  The initial and 
terminal amino acids (black boxes) of our CD14 constructs are displayed. 
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Figure 2.2:  Cloning and Site Directed Mutagenesis 
 
(A), Forward and reverse PCR cloning primers for both the Human HSCD14 and HLCD14 
constructs.  (B), A pDisplay vector (Invitrogen), containing ampicillin resistance for selection in 
E. coli and neomycin resistance for selection with geneticin (G-418) in mammalian cells, was 
modified by the Kranz lab to contain the Fc region of human IgG1 inserted in the NotI restriction 
site.  Restriction enzymes used for insertion of each construct (abbreviated HL, Hs, and M) are 
indicated.  (C), Forward and reverse primers for HsCD14 site directed mutagenesis by primer 
extension.  (D), Agarose gel electrophoresis of an Invitrogen 1kB DNA ladder (marker) and 
PvuII restriction enzyme digested DNA from select E. coli DH5a following mutagenesis to 
identify the presence of a C306S mutation in colonies #1 and #3.  (E), Sequencing of colony #3 
confirmed C306S mutation through identification of a TA nucleotide transversion. 
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Figure 2.3:  Human HLCD14 Protein Purification 
 
10% SDS-PAGE gels containing Precision Plus Dual Color Marker (BioRad) showing (A), 
elution samples #1-5 from Protein G affinity purification detecting HLCD14-Fc fusion protein. 
(B), Western blot with anti-Human CD14 polyclonal antibody of Protein G elution fractions #3 
and #4 showing bands in gel A are CD14. (C), Pooled Protein G elution fractions #1-5 with and 
without thrombin treatment showing incomplete cleavage of HLCD14-Fc. (D), flow through and 
elution fractions from Protein A affinity chromatography showing incomplete separation of 
HLCD14.  (E), flow through and elution fractions of Hi-Trap Q anion exchange chromatography 
on AKTA prime plus FPLC, performed as described in Materials and Methods in this Chapter, 
corresponding to fractions indicated in the elution profile that show incomplete separation of 
HLCD14.
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Figure 2.4:  Human HsCD14 Protein Purification 
 
(A), A 4-20% SDS-PAGE gradient gel stained with Coomassie blue shows major protein bands 
observed during various stages of human CD14 purification, including protein G, thrombin 
digestion, protein A, HiTrap Q, and size exclusion chromatography as indicated.  Fc fusion 
removal is observed during protein A purification.  (B), Small gel filtration (SGF) purification 
profile showing elution of a single peak (elutions #8 & #9) consistent with monomeric human 
CD14 protein, when compared to SGF column standards (GE Healthcare Calibration Kit).  
Figure 2.1(A), far right lane, shows the purity of this peak.  (C), A 4-20% SDS-PAGE gradient 
gel stained with Coomassie blue showing purified human CD14 with and without PNGaseF 
treatment as indicated. 
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Figure 2.5:  Human HsCD14 Initial Sparse Matrix Screen Results 
 
Published conditions from three commercially available sparse matrix screens (Wizard I and II 
from Emerald Biosystems and Crystal Screen I from Hampton Research) are listed, which were 
utilized during initial crystallization screening without modification to produce single crystals of 
HsCD14 shown in photographs of the corresponding hanging drops before crystal harvest. 
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Figure 2.6:  Human HsCD14 Best Initial Diffraction Data 
 
Diffraction imagefrom a 6.2 Å resolution data set of a single crystal of HsCD14, pictured in the 
hanging drop before harvest.  The crystal was grown during initial crystallization screening using 
the commercially available Wizard II #28 sparse matrix screen condition (Emerald Biosystems). 
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Figure 2.7:  Human HsCD14 Diffraction Data after Condition Optimization 
 
Diffraction image from a 4.02 Å resolution data set of a single crystal of HsCD14, pictured in the 
hanging drop before harvest (circled).  The crystal was grown in a handmade crystallization 
condition (indicated) during the crystallization optimization process. 
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Figure 2.8:  Human HsCD14 Best Diffraction Data after Full Condition Optimization 
 
Conditions from handmade crystallization conditions (K#25 optimized and K#19 best optimized) 
resulted in the best diffraction resolution after the full condition optimization, which is discussed 
in detail in the methods section of this chapter.  Resolution of diffraction data gathered from each 
single crystal, pictured in the hanging drop before harvest (circled), are indicated along with the 
crystallization condition.  The initial commercially available crystallization hit (Wizard II #28, 
Emerald Biosystems) and corresponding single crystal are shown for reference. 
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Table I:  Data Collection and Refinement Statistics 
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Figure 2.9:  Ramachandran Plot of Human CD14 (4GLP.pdb) 
  
Ramachandran plot (RAMPAGE) showing phi (ɸ) and psi (ψ) angles plotted on the x and  y 
axis, respectively, for each amino acid in the structure, over top of ‘favored’ and ‘allowed’ 
smoothed contours determined from high-quality data.  In our human CD14 crystal structure 
(4GLP.pdb), 69.5% (214/308) residues lie in the ‘favored’ contours (dark blue/dark orange), 
22.4% (69/308) lies in the ‘allowed’ contour (light blue/light orange) and 8.1% (25/308) residues 
are ‘outliers’ (white).
59 
 
Figure 2.10:  Human CD14 X-ray crystal structure 
 
(A), The X-ray crystal structure of human CD14 aa 26-335 is shown in ribbon (red).  Alpha 
helices (α1, α4, α5, α6, α7), beta strands (3-13), and the positions of cysteine residues (orange) 
are indicated.  The site directed mutagenesis of C306S is shown in magenta.  (B), Secondary 
structure alignment of human CD14 (red) and mouse CD14 (gray) was created using the default 
parameters of MultiSeq in VMD.  Disulfide bonds in human CD14 (orange) and mouse CD14 
(yellow) are indicated.  The site directed mutagenesis of C306S is shown in human CD14 
(magenta). 
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Figure 2.11:  Human CD14 structure based sequence alignment 
 
A structure based sequence alignment of human and mouse CD14 was created using the default 
parameters of MultiSeq in VMD.  MultiSeq output was used to assign human CD14 secondary 
structure elements upon visualization in VMD, and mouse CD14 secondary structure positions 
were derived from the header notation of 1WWL.pdb.  Numbered leucine rich repeat regions, 
which are conserved in location between both species, are shown in brackets ([LRR]).  Alpha 
helices (red rectangles), beta strands (yellow rectangles), turns and loops (black dashed lines) are 
indicated.  Cysteine residues (orange) and residues located in the rim of the N-terminal pocket 
are boxed for human CD14 (maroon) and mouse CD14 (blue). Since amino acid numbering is 
not standardized in previous publications, we have chosen to compare mouse and human CD14 
crystal structures by starting amino acid numbering at the first methionine residue.
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Figure 2.12:  Comparison of Mouse and Human CD14 N-terminal ligand binding pocket. 
 
 
(A), Mouse (gray) and human (red) CD14 ribbon structures are overlaid over mouse (translucent 
gray) and human (translucent red) CD14 space filling structures drawn in VMD.  CD14 
structures are rotated 90o relative to Figure 2.4(B).  The N-terminal hydrophobic binding pocket 
is indicated (black arrow).  (B), Space filling hydrophobicity structures were drawn in Chimera 
for human CD14 (left) and mouse CD14 (right).  The Kyte-Doolittle scale was used to compare 
hydrophobicity by showing hydrophobic (orange), neutral (white), and hydrophilic (blue) 
residues as well as glycosylation sites (red).   
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Figure 2.13:  Comparison of Mouse and Human CD14 Pocket Rim Residues 
 
(A), The structure of the rim of the predicted N-terminal ligand binding pocket of both mouse 
and human CD14 are overlaid.  Rim residues of human CD14 are denoted in red and those of 
mouse CD14 are denoted in blue.  Regions important for LPS binding, as determined from 
previous mutagenesis, blocking antibody, and epitope mapping studies are indicated in black 
with gray text.  (B), A space filling representation of the residues located on the rim of the 
predicted N-terminal ligand binding pocket of human and mouse CD14 are displayed in red and 
blue, respectively.  Regions important for LPS binding are displayed in black ribbon. 
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CHAPTER 3: 
 
Ligand Binding and Bioactivity of Purified CD142,3 
 
3.1 Introduction 
  In the work described in this chapter, we developed a source of mouse CD14 for our 
ligand binding crystallization studies.  We cloned, expressed, and purified a single mouse soluble 
CD14 construct (MCD14) from the cell supernatant of HEK 293F cells.  The previously 
published mouse CD14 x-ray structure encompassed aa 5-313, as numbered from the start of the 
mature protein after N-terminal secretion signal removal (69).  Our MCD14 construct ended with 
the same C-terminal amino acid, but unlike the crystal structure, we maintained the authentic N-
terminal secretion signal (designated aa 1-15).  Thus, our purified mouse MCD14 protein 
encompassed aa 1-328, as numbered from Met 1. 
 As described in Chapter 1, soluble CD14 is known to bind a number of acylated TLR4 
and TLR2/1 ligands.  We characterized the ability of both mouse MCD14 and human HsCD14 
proteins utilized in our crystallography studies to bind these acylated ligands employing two 
ligand binding detection methods.  First, we conducted gel shift analysis using 4-20% native 
PAGE.  Using this assay, we tested the ability of our purified proteins to bind the Ra chemotype 
of E. coli LPS, which signals through TLR4/MD-2 as described in Chapter 1.  Upon ligand 
binding, the increased negative charge present in bound LPS phosphate groups induces a 
                                                          
2 Reprinted in part with permission from Kelley, S. L., Lukk, Tiit, Nair, S. K., and R. I. Tapping. (2013). “The crystal 
structure of human soluble CD14 reveals a bent solenoid with a hydrophobic amino-terminal pocket.” J. Immunol. 
190 (3): 1304-1311. 
3 Reprinted in part with permission from Ranoa, D. R., Kelley, S. L., and R. I. Tapping. (2013). “Human LBP and CD14 
independently deliver triacylated lipoproteins to TLR1 and TLR2 and enhance formation of the ternary signaling 
complex.” J. Biol. Chem. 288: 9729-9741. 
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downshift of the CD14-LPS complex in a native PAGE, which can be visualized using 
Coomassie blue staining.  Second, we tested the ability of our purified proteins to bind various 
ligands using the Octet QK first generation system (ForteBio).  TLR4/MD-2 ligands tested using 
this method included the rough Ra chemotype of E. coli LPS and smooth LPS containing the full 
O-antigen and core oligosaccharide group from S. Minnesota.  Additionally, two TLR2/1 ligands 
that are shuttled by CD14 were also tested.  A 31 kD N-terminal tripalmitoylated (Pam3) 
lipoprotein called Outer Surface Protein A (OspA) (187), which was purified from Borrelia 
burgdorferi bacterial extract, and a commercially available synthetic triacylated lipoprotein 
mimic of the N-terminus of OspA called Pam3CSK4.  Real-time, label-free ligand binding 
detection using the Octet QK was conducted on these ligands to corroborate our native 
polyacrylamide gel shift ligand binding results. 
 The ForteBio Octet QK automated system uses up to eight optical biosensors per 
experiment in a “Dip and Read” format, where a robotic arm dips the biosensors from one well 
to another in a 96-well, black, flat bottom, polypropylene microplate with a 200 L sample 
volume.  The biosensors have a coated surface for immobilization of the receptor protein being 
studied.  In our case, we utilized protein A coated biosensor to immobilize the Fc fusion of 
HsCD14, though other coating surfaces are commercially available.  The thickness of the sensor 
(binding, nm) is measured in the Octet QK using bio-layer interferometry, which measures the 
change in wavelength between two spectrums (intensity vs. wavelength (nm)) recorded for 
reflections of white light off of an internal reference layer and the biosensor tip.  As the 
HsCD14-Fc protein binds the protein A biosensor, the thickness of the sensor surface (binding, 
nm) increases over time (seconds), creating a real-time ligand binding curve. 
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 Most importantly, we verified both our human and mouse purified CD14 proteins that 
were utilized in crystallography studies are biologically active.  As mentioned in Chapter 1, 
soluble CD14 functions to enable cells that express TLR4/MD-2, but do not express membrane 
bound CD14, to be sensitive to LPS.  Since epithelial cells do not produce membrane bound 
CD14, we could identify the bioactivity of our purified human and mouse CD14 proteins by 
measuring their ability to bind and deliver LPS to stimulate production of the chemokine IL-8 by 
TLR4/MD-2 signaling.  Thus, we were able to measure the bioactivity of purified human and 
mouse CD14 induced production of IL-8 using an ELISA IL-8 detection system.  Additionally, 
small gel filtration mixing studies using human CD14, which was purified as described in this 
Chapter, detected human CD14 bioactivity, because human CD14 was able to bind and deliver 
OspA to catalytically form TLR2/1/OspA complexes, independent of LBP (188). 
 Our efforts to create a ligand-bound crystal of mouse CD14 will also be discussed in this 
chapter.  We conducted initial crystallization sparse matrix screening for mouse MCD14 similar 
to the work described in Chapter 2 for human HsCD14 and determined conditions where our 
mouse MCD14 protein crystallized.  However, in ligand bound crystallization studies, both 
purified proteins did not produce single crystals of sufficient size or quality for diffraction 
studies. 
 
3.2 Materials and Methods 
 
3.2.1 Reagents 
 The same cloning, expression, and protein purification reagents described in the 
Materials and Methods section of Chapter 2 were utilized in the cloning, expression and 
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purification of MCD14.  Sources of TLR4/MD-2 reagents included smooth Salmonella enterica 
serotype minnesota LPS (Sigma L6261) and the Ra chemotype of Escherichia coli EH100 LPS 
(Sigma L9641).  Sources of TLR 2/1 ligands included recombinant outer surface protein A 
(OspA) purified from Borrelia burgdorferi bacterial extract (Recombitek Lyme, purchased from 
Merial, Inc. (Athens, GA)) and a synthetic, racemic mixture of N-palmitoyl-S-[2,3-
bis(palmitoyloxy)-propyl]-(R)-cysteinyl-(lysyl)3-lysine (Pam3CSK4; EMC Microcollections, 
Tuebingen, Germany).  ForteBio Octet wash steps utilized PBS-T buffer (1X PBS with 0.05% 
Tween 20 detergent; Sigma P1379).  Bioactivity assay reagents included RPMI 1640 media 
(Corning; 15040CV), bovine serum albumin (BSA; Sigma A9418), human serum albumin 
(Octopharma, Hoboken, NJ), and human serum obtained from the peripheral blood of 
anonymous donors from blood draws performed by Dr. Brian Hart and Song Jiang.  Monoclonal 
anti-CD14 antibodies (28C5 and 63D3) and a polyclonal Goat anti-LBP antibody were kind gifts 
from Dr. Peter Tobias, The Scripps Research Institute, La Jolla, CA.  Human LBP from Xoma 
Corp. (Berkley, CA) was a kind gift from Dr. Jerrold P. Weiss and Dr. Theresa L. Gioannini, 
University of Iowa, Iowa City, IA.   
 
3.2.2 Mouse CD14 Cloning, Expression, and Purification 
 The mouse CD14 constructs was created using the same modified pDisplay vector system 
described in Chapter 2 Materials and Methods.  Briefly, the forward primer contained an EcoRI 
cleavage site, Kozak sequence, and a portion of the N-terminal secretion signal of mouse CD14 
beginning at aa 1.  The reverse primer consisted of the C-terminal coding region of mouse CD14 
from aa 328 in addition to a NheI cleavage site and thrombin digestion site (LVPRGS).  This set 
of primers (Figure 3.1A) was utilized to amplify mouse CD14 (aa 1-328) from genomic DNA 
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(ATCC) using PCR as described in Chapter 2.  After PCR, EcoRI and NheI restriction enzymes 
were used to digest the MCD14 PCR product and modified pDisplay vector (Figure 3.1B), a 
kind gift from Dr. David Kranz, University of Illinois, Urbana-Champaign.  Following agarose 
gel electrophoresis, the following sized bands were observed:  undigested pDisplay vector (6,154 
bp), EcoRI and NheI digested pDisplay vector (5,542 bp & 612 bp), and EcoRI and NheI 
digested MCD14 PCR product (976 bp).  The vector and insert were ligated by T4 DNA ligase 
(Invitrogen) and transformed into E.coli DH5α cells using heat-shock as directed in the 
manufacturer’s protocol (Invitrogen).  Positively transformed colonies were selected on LB-
Ampicillin plates grown overnight in the 37oC warm room.  Conformation of transformation 
using DNA extraction, EcoRI and NheI restriction enzyme digestion, agarose gel electrophoresis, 
sequencing, transfection of HEK 293F cells, protein expression, and selection of stable lines 
were also completed as described in Chapter 2 Materials and Methods. 
 PNGaseF treated MCD14 protein utilized in later ligand binding crystallization studies 
was purified using the identical buffers and method described for HsCD14 in Chapter 2 
Materials and Methods.  Native Mouse CD14 protein was purified using a four-step 
chromatographic procedure as described in Chapter 2 Materials and Methods, with the following 
variations.  First, Protein G sepharose was used to affinity extracted MCD14-Fc fusion protein 
from the supernatant of two liters of HEK 293F cells.  Following thrombin cleavage, protein was 
injected using a 10 mL loop onto an ÄKTAprime™ plus FPLC (GE Healthcare) fitted with Hi-
Trap Q anion exchange chromatography using a linear NaCl gradient (0.02 M - 1 M) in 0.02 M 
HEPES, pH 7.5 run at a 1 ml min-1 flow rate.  Pooled fractions containing HsCD14 were 
concentrated to 1 mL using an Amicon Ultra-15 unit (Millipore) and injected onto two tandem 
Protein A columns run with 0.02 M HEPES, pH 7.5 buffer using a 1 ml min-1 flow rate for free 
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Fc removal.  Flow through fractions containing MCD14 were pooled and injected into size-
exclusion chromatography using a Superdex 200 column (GE Healthcare) equilibrated with 0.02 
M HEPES, pH 7.5 and 0.1 M NaCl at a flow rate of 0.4 mL min-1.  Final SGF fractions 
containing MCD14 were pooled and concentrated mg ml-1 using an Amicon Ultra-4 unit 
(Millipore) as measured by Pierce BCA assay (Rockford, IL).  This four column purification 
process yielded ~2-3 mg L-1 soluble, mouse CD14 with >90% purity as ascertained visually by 
SDS-PAGE (Figure 3.1C).  The SGF elution profile indicated fractions containing MCD14 
which was confirmed visually on 10% SDS-PAGE with Coomassie staining (Figure 3.1D). 
 
3.2.3 Generation of Human CD14 for Small Gel Filtration Mixing Studies 
 Human soluble CD14 protein was cloned and expressed as previously described (189), 
and similarly purified with the following exceptions.  Briefly, human CD14 (aa 1-337) was 
amplified from genomic DNA and cloned into a modified pDisplay vector preceding a thrombin 
cleavage site (LVPRGS) and the Fc domain of human IgG1.  The final construct was sequenced 
(University of Illinois Urbana-Champaign Sequencing Center) following site-directed 
mutagenesis (C306S) via primer extension to avoid unnatural disulfide bonding resulting from 
the truncated coding region of our construct.  Following transfection and stable selection of 
human HEK 293F cells (Invitrogen), human soluble CD14 was purified from cell supernatant in 
three chromatographic steps, including protein G affinity chromatography, thrombin cleavage, 
protein A affinity chromatography, and size exclusion chromatography.  Finally, fractions 
containing CD14 were pooled and concentrated to 10 mg/mL using an Amicon Ultra-4 unit 
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(Millipore) as measured by Pierce BCA assay.  Human soluble CD14 (aa 1-337, C306S) purified 
by this method was stored at 4oC for up to six months prior to use (188). 
 
3.2.4 Native Polyacrylamide Gel Shift LPS Binding Assay 
The binding of LPS by native mouse CD14 (Figure 3.2A and 3.2B), native human 
HsCD14 (Figure 3.3A), or PNGaseF treated human CD14 (Figure 3.3B) was detected by a 
native polyacrylamide gel shift method (190).  Ten micrograms CD14 was mixed with a 2:1 
molar ratio of the Ra chemotype of E. coli LPS (Sigma), with or without a 1:100 molar ratio of 
LBP:CD14 (LBP kindly provided by Dr. Jerrold Weiss, University of Iowa).  The reactions were 
incubated for 1 hr or less as indicated (pre-incubation time) at 37oC in a total volume of 5 L in 
PBS buffer containing 0.01M EDTA.  5 L bromophenol blue with glycine dye was added and 
each sample was loaded in a 4-20% Mini-PROTEAN TGX precast gel, pH 6.8 (Bio-rad) run at 
100V in the manufacturer recommended running buffer without SDS at 4oC for 3 hours. 
 
3.2.5 ForteBio Octet QK Ligand Binding Assay 
 Protein A biosensors (ForteBio) were equilibrated in a 96 well, flat bottom, black, non-
binding polypropylene microplate (Greiner Bio One; #655900) placed in the sample block of the 
ForteBio Octet QK in 0.2 mL PBS for 2 minutes.  Immediately after equilibration, the protein A 
biosensors were transferred by robotic arm into the adjacent wells to immobilize of 0.03 M 
HsCD14-Fc for 30 minutes.  After a 20 minute wash in PBS-T buffer, the HsCD14-Fc 
containing biosensors were placed in wells containing a 0.2 mL ligand solution with or without 
LBP for 1 hour of ligand binding.  In Figure 3.4A, well A contained 0.03 M LBP (pink), well B 
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contained 0.03 M OspA and 0.03 M LBP (1:1 molar ratio) (orange), well C contained 0.2 M 
the Ra chemotype of E. coli and 0.1 M LBP (2:1 molar ratio) (red), and well D contained 0.2 
M S. Minnesota LPS and 0.1 M LBP (2:1 molar ratio) (blue).  In Figure 3.4B, well A 
contained the nonblocking anti-CD14 63D3 antibody (green) and well B contained the blocking 
anti-CD14 28C5 antibody (pink).  At this point the procedure differs as indicated below.  In 
Figure 3.4A, a 30 minute incubation in PBS-T buffer is followed by a 1 hr incubation for LBP 
detection using 0.3 M polyclonal anti-LBP, followed by a 30 minute PBS-T buffer wash step 
(pink, orange, blue, and green).  In Figure 3.4B, a 1 hr incubation with 0.03 M OspA and 0.03 
M LBP (1:1 molar ratio) followed ligand binding, followed by a 20 minute PBS-T buffer wash 
step. 
 
3.2.6 IL-8 Bioactivity Assay  
 Various concentrations of the Ra chemotype of E. coli LPS (Sigma) were preincubated 
for 1 hr (Figure 3.5A) or 1 hr or overnight (ON) (Figure 3.5B) at 37°C at a 2:1 molar ratio 
LPS:CD14 in RPMI media containing 1% human serum albumin for both SGF purified Human 
HsCD14 (Figure 3.5A) and Mouse MCD14 (Figure 3.5B).  For some reactions, LBP was added 
as a catalyst at a 1:100 molar ratio of LBP:CD14.  We included a natural source of soluble CD14 
(2% human serum; Figure 3.4A) as a positive control.  The bioactivity of CD14 in these 
reactions was assessed using SW620 human epithelial cells that express TLR4/MD-2 and lack 
detectable levels of membrane CD14 (128).  SW620 cells were cultured in RPMI complete 
media containing 1% BSA, seeded in a 96-well plate at a density of 1.0 x 106 cells/well, and 
allowed to adhere for 1 hr at 37°C, 5% CO2. To remove serum, we carefully washed SW620 
cells four times with PBS, two times with Life Technologies FreeStyle 293 Expression Media 
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(Invitrogen), and two times with RPMI containing 1% human serum albumin.  Pre-incubated 
samples containing CD14 and LPS were added to the carefully washed SW620 epithelial cells.  
Cell supernatant was harvested 6 hrs later, and IL-8 production was measured using a human IL-
8 Cytoset sandwich ELISA kit (Invitrogen).  In the ELISA, mouse anti-human IL-8 capture 
antibody was immobilized in a 96 well plate format and blocked with 1% bovine serum albumin 
(Sigma) in PBS.  Cellular supernatant was applied for two hours.  After a wash step with 1% 
BSA in PBS, biotinylated anti-human IL-8 detection antibody was applied, followed by a 1% 
BSA/PBS wash.  Streptavidin conjugated horseradish peroxidase (HRP; R&D Systems) was 
applied and developed with the substrate o-phenylenediamine (OPD; Sigma; P9029), which 
yields a water soluble yellow-orange color detectable at ~490 nm by microplate reader (BioRad 
Model 680). 
 
3.2.7 Initial Crystallization Screening of Mouse CD14 
 For the initial sparse matrix screening, the hanging drop vapor diffusion methods was 
utilized to set out 2 l drops containing native MCD14 (10 mg/mL) combined in equal volume 
with commercially available sparse matrix screen conditions (Hampton Research Crystal Screen 
I, Crystal Screen II, Natrix, and Salt Reaction and Emerald Biosystems Wizard I and II) or 
handmade crystal screen conditions targeting the previously published mouse CD14 
crystallization condition (1 l protein solution and 1 l of crystallization buffer containing 100 
mM sodium HEPES (pH 7.5), 1.9 M Li2SO4, and 5 mM NiCl2) (69).  Crystallization trays were 
set up and monitored for microcrystals, crystal clusters, or single crystals (Figure 3.7), using 
methodology previously detailed in Chapter 2 Materials and Methods. 
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3.2.8 Initial Crystallization Screening of Mouse CD14-LPS Complexes 
 Native or PNGaseF deglycosylated MCD14 (and HsCD14; data not shown) were 
incubated with a 2:1 molar ratio of the Ra chemotype of E. coli LPS in the presence of a 1:100 
molar ratio of LBP:CD14 at 37oC for 1 hr immediately prior to setting out crystallization trays.  
This protein mixture was then screened against the same commercially available sparse matrix 
crystallization kits utilized in the initial crystallization screening methodology described above.  
Each condition was tested on a 12 mm x 0.22 mm siliconized glass cover slide (Hampton 
Research) over a VDX48 plate with sealant (Hampton Research) by mixing 1 l of each 
screening solution with 1 µl LPS containing protein solution [10 mg ml-1 MCD14 or HsCD14 
protein in 0.02 M HEPES, pH 7.5 and 0.1 M NaCl (MCD14) or 0.02 M Tris-HCl, pH 8.5 and 0.1 
M NaCl (HsCD14)] equilibrated against 300 µl screening solution in the reservoir and set out at 
RT.   
 
3.3 Results 
 
3.3.1 Purified Mouse CD14 
 We cloned, expressed, and purified mouse CD14 (MCD14) in an effort to obtain a source 
of protein useful for ligand bound crystallization studies.  Forward and mouse CD14 PCR 
primers were created to encompass aa 1-328 (Figure 3.1A), terminating at the same residue as 
the x-ray crystal structure of mouse CD14 (69).  Ligating the PCR product into a modified 
pDisplay vector using EcoRI and NheI digestions sites (Figure 3.1B) enabled protein expression 
in eukaryotic cells.  Following stable transfection of human embryonic kidney HEK 293F cells, 
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mouse CD14 was purified using protein G sepharose beads, thrombin digestion, HiTrap Q anion 
exchange, protein A affinity purification (to further remove free Fc), and small gel filtration 
(Figure 3.1C).  Purification resulted in >90% pure MCD14 protein, as judged SDS-PAGE 
stained with Coomassie blue and SGF purification profile (Figure 3.1D).  
 
3.3.2 Purified Human and Mouse CD14 Bind E. coli LPS 
 One of our first questions following purification was whether or not purified HsCD14 or 
MCD14 is able to bind and shuttle ligands to TLRs.  We set out to answer the question of LPS 
binding using a native polyacrylamide gel shift method (190).  As mentioned previously, when 
CD14 binds LPS, the CD14-LPS complex shifts relative to the position of CD14 alone, due to 
the increased negative charge present from the bound LPS phosphate groups.  As shown in 
Figure 3.2A lanes 3-9, 13, and 15, mouse CD14 is capable of binding the Ra chemotype of LPS 
indicated by downward shifts in a 4-20% gradient native PAGE.  The binding reaction involves a 
1 hr incubation at 37oC of CD14 and LPS in the presence of a catalytic amount of LBP (1:100 
LBP:LPS molar ratio).  A 1.5-2 molar ratio of LPS:MCD14 facilitated the most complete shift or 
complex formation.  Therefore, we utilized a 2:1 molar ratio of LPS:MCD14 as a loading 
condition for CD14 ligand binding crystallization studies.  Further gel shift analysis included 
optimization of incubation conditions.  For example, in Figure 3.2B we varied incubation time.  
Thirty minutes incubation also resulted in complex formation (as indicated by a shift in protein 
mobility), and in further gel shift analysis (data not shown) we found CD14 and LPS incubated 
for five minutes in the presence of LBP was sufficient to drive complex formation.  Similarly, 
native (Figure 3.3A) and deglycosylated (Figure 3.3B) human HsCD14 bound the Ra 
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chemotype of LPS when mixed with a 2:1 molar ratio of this ligand in the presence of 1:100 
LBP:LPS molar ratio.  However, without LBP, additional incubation time was needed to drive 
complex formation as evidenced by mixing a 2:1 molar ratio of LPS:CD14 with (lane 3) and 
without (lane 2) LBP (Figure 3.3B). 
 
3.3.3 Octet and Small Gel Filtration Mixing Studies Confirm Ligand Binding to Human CD14 
 Numerous ligands capable of binding human HsCD14-Fc fusion were assessed through 
Octet QK ligand binding studies (summarized in Figure 3.4A).  We found that immobilized 
human HsCD14-Fc is able to bind B. burgdorferi OspA (orange), the Ra chemotype of E. coli 
LPS (red), and S. minnesota LPS (blue) in the presence of LBP.  Although we did not detect 
binding of LBP alone (pink) to immobilized HsCD14-Fc, we wondered if the binding observed 
was entirely due to OspA or LPS ligand binding, or if LBP was retained in the final complex.  To 
test for LBP retention, in the final complexes we measured the binding of polyclonal anti-LBP to 
the captured complexes.  We found complexes formed using rough LPS (from E. coli) retained 
bound LBP during the capture stage, as indicated by the presence of a binding curve upon 
addition of an anti-LBP antibody.  Similarly, complexes containing smooth S. minnesota LPS 
also bound the anti-LBP, indicating LBP retention to a lesser extent than rough LPS.  However, 
complexes formed using the ligand OspA did not show a detectable binding curve with anti-LBP 
antibody, indicating that OspA binds immobilized CD14 without LBP retention. 
 In a separate study shown in Figure 3.4B, we assessed the ability of anti-CD14 
antibodies 63D3 and 28C5 to block OspA binding to immobilized HsCD14-Fc fusion.  Anti-
CD14 antibody 28C5 binds CD14 near the N-terminal LPS binding site and block the LPS 
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binding and cellular activation functions of CD14 (128).  In contrast, the anti-CD14 antibody 
63D3 does not bind the N-terminal portion of CD14 and does not block LPS binding to CD14.  
In both Octet QK experiments, we immobilized 0.03 M human HsCD14-Fc on a protein A 
biosensor.  As shown in Figure 3.4B, both 63D3 (green) and 28C5 (pink) were capable of 
binding to immobilized HsCD14-Fc as measured in the capture step.  As expected, incubation of 
the CD14 bound sensors with OspA and LBP (at a 1:1 molar ratio) facilitated complex 
formation.  The 28C5 antibody blocked OspA binding, but the 63D3 antibody did not.  These 
results indicate that the binding site of OspA is physically located at or near the binding site of 
LPS in the N-terminus of CD14.   
 
3.3.4 Purified Human and Mouse CD14 Are Bioactive 
 In addition to ensuring that our purified HsCD14 and MCD14 proteins were capable of 
binding ligands including LPS, we also measured their ability to stimulate LPS responses in 
human cells.  As mentioned previously, human epithelial SW620 cells express MD-2 and TLR4, 
but lack membrane bound CD14.  When CD14 shuttles LPS to the SW620 cells, they are 
stimulated to secrete pro-inflammatory cytokines and chemokines, including IL-8, which can be 
measured in culture supernatants by ELISA.  Using methodology described in detail in the 
Materials and Methods section of this chapter, 0.01-100 ng/mL of the Ra chemotype of E. coli 
LPS was incubated for 1 hr (or overnight where indicated) at 37oC with and without a 1:100 
molar ratio of LBP:LPS in either the presence or absence of 1 g/mL HsCD14 (Figure 3.5A) or 
MCD14 (Figure 3.5B).  These reactions were then added to SW620 cells and secreted IL-8 
chemokine levels were monitored by ELISA.  In the absence of LBP or CD14, only the highest 
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concentration of LPS was capable of stimulating IL-8 production (blue).  When HsCD14 was 
added to LPS and LBP (red), SW620 cells became 100 fold more sensitive to the presence of 
LPS compared to LBP alone (orange) (Figure 3.5A).  To confirm our assay was capable of 
detecting the full activity of LBP and CD14, we tested two percent human serum as a positive 
control and a natural source of LBP and soluble CD14 (127).  Two percent human serum 
induced similar levels of IL-8 as that of LBP and our purified CD14 protein (green).   
 Likewise, purified mouse CD14 (green or red) was able to stimulate 10-100 fold greater 
levels of IL-8 secretion than that of LBP catalysis alone (orange) (Figure 3.5B).  In this 
experiment, we saw no difference between 1 hr (red) and overnight (green) incubation of 
MCD14 with LPS with and without LBP.  However, in a similar bioactivity assay with HsCD14, 
we saw overnight incubation severely inhibited the ability of the HsCD14 protein to stimulate 
cells to produce IL-8, indicating lower protein stability compared to MCD14 following 
prolonged incubation at 37oC (data not shown). 
 A separate small gel filtration mixing study further confirmed the bioactivity of purified 
human CD14.  In this work, our soluble human CD14, purified as described in the Materials and 
Methods in this Chapter, is able to bind and catalytically deliver OspA to form 
TLR2/TLR1/OspA complexes without the requirement for LBP (188).  A two hour 
preincubation at 37oC of OspA, soluble TLR2, and soluble TLR1, in the absence of both CD14 
and LBP, was unable to form a TLR2/1/OspA complex detectable by small gel filtration (SGF) 
(data not shown).  However, addition of our purified human CD14 enabled detectable complex 
formation in the SGF elution profile without CD14 retention, which was confirmed by western 
blot detection of TLR2, TLR1, and CD14 using anti-TLR2, anti-TLR1, and polyclonal anti-
CD14 antibodies in the corresponding SGF elution fractions (data not shown).  Taken together 
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with our ForteBio Octet results showing human CD14 is able to bind OspA without the retention 
of LBP, these subsequent small gel filtration mixing studies show CD14 is able to deliver bound 
OspA to TLR2/1 in a catalytic manner independent of LBP, which further endorses the 
bioactivity of our purified human CD14. 
 
3.3.5 Initial Crystallization Screening of Mouse CD14 
 We created a handmade crystallization screen that slightly varied the precipitate, buffer, 
and salt components around the previously published mouse CD14 crystallization condition (1.9 
M Li2SO4, 100 mM HEPES, pH 7.5, and 5 mM NiCl2).  Although our purified mouse CD14 was 
unable to crystallize at that condition, potentially due to differences in our purification system, 
we were able to obtain crystals of MCD14 protein under different experimental conditions.  Our 
initial screening of MCD14 used commercially available kits, as mentioned in the Materials and 
Methods sections of this Chapter and Chapter 2, including Wizard I, Wizard II, and Crystal 
Screen I.  We also varied crystallization temperature, including an examination of 18oC and 
room temperature conditions.  The crystallization conditions capable of producing single crystals 
or crystal clusters are shown in Figure 3.6.  We did not pursue diffraction of these conditions 
because the mouse CD14 crystal structure had already been published.  However, we did use this 
information to target ligand binding crystallization conditions. 
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3.3.6 Lack of Diffraction Quality Crystals of CD14-LPS Complexes 
 A ligand bound crystal structure of CD14 with LPS will greatly improve our 
understanding of the molecular interactions between LPS and this receptor.  Ligand bound 
crystal structures are difficult to achieve, especially utilizing a non-homogenous, non-small 
molecule and highly amphipathic ligand capable of forming aggregates like LPS.  However, 
since the Ra chemotype of LPS which lacks the O-antigen was successfully crystallized in 
complex with MD-2/TLR4 (77), we began our ligand binding crystallization studies using this 
LPS chemotype.  In setting up these experiments, we wished to load CD14 with LPS and then 
purify the CD14-LPS complexes away from unbound LPS.  Since loading CD14 with LPS prior 
to Protein G affinity purification was not an option due to the large cell supernatant volume 
(~2L) we were utilizing, we began by loading CD14 with LPS immediately following Protein G 
affinity purification (just prior to thrombin cleavage and Hi-Trap Q anion exchange), prior to 
protein A affinity purification, and prior to small gel filtration with a 2:1 molar ratio of 
LPS:CD14, as measured by BCA assay, and a catalytic amount of LBP (1:100 LBP:CD14 molar 
ratio).  We found that incubation of CD14 with LPS prior to thrombin digestion reduced the 
cleavage reaction efficiency (data not shown).  Introduction of LPS prior to Protein A 
purification of CD14 led to a large reduction in protein yield following purification and increased 
column pressure, possibly due to the formation of CD14-LPS aggregates during column 
chromatography.  Similarly, we found that introduction of LPS immediately prior to small gel 
filtration led to aggregation of LPS on the Superdex 200 column, which required prolonged 
stringent washing and rinsing steps (70% ethanol or 1 M NaOH followed by water and buffer re-
equilibration) prior to beginning the next round of purification.   
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 Although we set out crystallization trays of CD14 protein loaded with LPS by LBP after 
HiTrap Q anion exchange, after protein A affinity chromatography, and after purification 
following a second round of small gel filtration, we did not obtain any promising crystallization 
leads.  Instead, the data presented in this chapter was produced by the most straightforward way 
of introducing LPS, where CD14 was loaded with LPS by LBP immediately following protein 
purification (prior to crystallization).  In this approach, we incubated LPS with human or mouse 
CD14 in a 1:1 molar ratio with LPS with and without LBP at 37oC overnight immediately prior 
to setting out trays, in an effort to give CD14 enough time to interact with LPS.  Additionally, in 
the initial sparse matrix screening results using mouse CD14 (Figure 3.7), we used conditions 
we previously found to be capable of producing evidence of LPS binding by native 
polyacrylamide gel shift and ForteBio Octet QK analysis (2:1 molar ratio of LPS:CD14 and a 
1:100 molar ratio of LBP:CD14) and we pre-incubated the mixture at 37oC for 1 hr before setting 
out the initial sparse matrix crystallization screen. 
 Using PNGaseF treated mouse CD14 protein, purified as described in Materials and 
Methods, we observed phase separation and protein aggregation in the hanging drops of Wizard I 
#28 and Wizard I #30 after <1 day at room temperature (Figure 3.7).  These outcomes were 
typical of all of the crystallization trials involving human or mouse CD14 incubated with LPS in 
either the presence of or the absence of LBP.  The best result from all CD14-LPS crystallization 
studies was observed after 45 days in Wizard I #7 (Figure 3.7).  Only four microcrystals were 
observed, but these crystals were too small to harvest for diffraction analysis.  Instead of further 
pursing optimization of conditions to enhance these non-diffraction quality crystals, we 
refocused our protein production and crystallization efforts to obtain an x-ray crystal structure of 
human CD14 without ligand bound (189).  The human CD14 crystallization condition we 
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determined was utilized to screen human and mouse CD14 after LPS loading, resulting in no 
diffraction quality CD14 crystals with ligand bound. 
 
3.4 Discussion 
 
 In this Chapter, we described the cloning, expression, and purification of mouse MCD14 
protein.  We determined the capacity of this protein and our purified HsCD14 protein to bind 
LPS after incubation with LBP at 37oC using native polyacrylamide gel shift analysis.  To further 
support our native polyacrylamide gel shift data, we confirmed HsCD14-Fc LPS binding using 
ForteBio Octet QK.  Smooth and rough forms of LPS were capable of producing detectable 
binding curves with immobilized human HsCD14.  We also found human CD14 bound the 
lipoprotein OspA.  Similarly, our ForteBio Octet data showed LBP retention in complexes 
generated with either form of LPS, but not with OspA lipoprotein.  In support of these findings, 
small gel filtration mixing studies showed further purified human CD14 was able to deliver 
bound OspA to TLR2/1 catalytically without the need for LBP (188).  Also using ForteBio 
Octet, we also found less LBP was retained with smooth LPS from S. minnesota compared to 
rough LPS from E. coli.  One possible explanation for the retention of LBP in this in vitro system 
is that the equimolar ratio of LBP and CD14 in the presence of a 2 fold excess molar ratio of LPS 
may have shifted CD14 from its primary role of shuttling LPS to TLR4 to its alternative function 
as a cell surface receptor for LBP opsonized LPS aggregates leading to clearance of LPS (48, 49, 
52, 191).  Although the mechanism and molecular interactions involved are undetermined, 
membrane bound CD14 is known to control LPS-induced endocytosis of TLR4 (192). 
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 Wooten and colleagues (187) found that 28C5, an anti-CD14 antibody that inhibits LPS-
mediated cell activation, also inhibits activation induced by OspA, a triacylated lipoprotein of 
Borrelia.  In support of this we found in our studies that the inhibitory 28C5 antibody blocks the 
binding of OspA to HsCD14.  Since OspA contains Pam3, we also tried to detect the synthetic 
TLR2/1 agonist Pam3CSK4 binding to CD14 using the ForteBio Octet QK Green instrument.  
However, Pam3CSK4 binding was not detected, an observation that could be due to the minimum 
ligand molecular weight (10 kD) required for detectable bio-layer interferometry signaling 
greatly exceeded the molecular weight (1.5 kD) of monomeric Pam3CSK4.  This limitation 
suggests that even if Pam3CSK4 is able to bind HsCD14-Fc, we would not be able to detect it 
unless it bound in large aggregates or retained LBP upon binding.  Repeating this experiment 
with the second generation ForteBio Octet Red96 system may enable detection of binding 
because the minimum ligand molecular weight requirement for this newer instrument is 150 Da.  
We also determined both MCD14 and HsCD14 purified proteins are capable of mediating the 
responses of SW620 epithelial cells to the Ra chemotype of LPS.  Studies also confirmed the 
bioactivity of purified human CD14 by its ability to form TLR2/1/OspA complexes in small gel 
filtration (188).  Taken together, these results suggest purified mouse and human CD14 proteins 
are bioactive by their capacity to bind and deliver ligands to TLR4/MD-2 and TLR2/1 
complexes.  Verifying that our purified CD14 proteins are able to bind ligands, determining 
loading conditions, and confirming biologically activity after purification was important before 
advancing these proteins through ligand binding crystallization trials. 
 Our x-ray structure of human CD14 presents a good framework to discuss our ligand 
binding crystallization results.  As described in Chapter 2, we confirmed the presence of an N-
terminal hydrophobic pocket in human CD14, which is predicted by a number of deletional, 
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mutational, and antibody blocking studies to be the LPS binding site.  Our x-ray crystal structure 
of human CD14 also advanced our understanding of the residues involved in the rim of this N-
terminal pocket, enabling us to predict rim residue repositioning upon ligand binding.  
Additionally, we were able to identify a pocket adjacent hydrophobic patch that may interact 
with LPS acyl chains that are not fully sequestered in the pocket.  So, we focused on solving a 
ligand bound structure to confirm these results and to identify molecular interactions between 
CD14 and its ligand. 
 Despite optimizing loading of human and mouse CD14 with ligand and exploring various 
crystallization conditions, we were unable to obtain diffraction quality ligand bound CD14 
crystals.  Individual and crystal clusters of purified human and mouse CD14 were produced 
using commercially available crystallization conditions, which we used to screen crystallization 
of human and mouse CD14 in the presence of the hexaacylated Ra chemotype of LPS.  One 
commercially available condition (Wizard I #7) produced four potential microcrystals of mouse 
CD14 in the presence of LPS, which were of insufficient quality or size to carry forward for 
diffraction studies.  The majority of hanging drops resulted in disordered aggregates and phase 
separation.  Since we used the same LPS loading conditions that showed CD14-LPS complex 
formation in native PAGE, we expect CD14-LPS complexes were formed, but the hexaacylated 
Ra chemotype of LPS may not have been an ideal ligand for crystallization studies with CD14, 
despite its previous crystallization with TLR4/MD-2 (77, 103) and its biological significance.  
Since our crystal structure of human CD14 (189) revealed a relatively smaller N-terminal 
hydrophobic pocket compared to MD-2, we believe the hexaacylated LPS ligand may not be 
fully accommodated by our pocket.  Thus, the disordered aggregates and phase separation we 
observed during crystallization may have been induced by the unsequestered acyl chains of our 
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CD14-LPS complexes associating with each other and thwarting our crystallization efforts.  
Futures work to obtain a ligand bound crystal structure of CD14 may be made possible through 
the use of ligands with smaller numbers of acyl chains, like the synthetic diacylated or 
tetraacylated inhibitors discussed in Chapter 2, which are able to competitively block LPS 
binding to CD14 (183-185) and may be completely sequestered in the pocket of CD14.  A ligand 
bound structure of CD14 would confirm the N-terminal ligand binding site and our identification 
of the adjacent hydrophobic patch binding site, offering beneficial insight for drug development 
by further characterizing important molecular interactions between CD14 and its ligand. 
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Figure 3.1:  Mouse CD14 (MCD14) cloning, expression, and purification 
 
(A), Forward and reverse PCR primers for MCD14; (B), modified pDisplay vector map; (C) 
10% SDS-PAGE gel stained with Coomassie blue R250 shows MCD14 protein purity during 
each stage of purification.  The final lane of this gel corresponds to the single symmetrical peak 
in (D), the small gel filtration elution profile, and both show MCD14 is >90% pure following 
purification.  
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Figure 3.2:  Mouse CD14 (MCD14) LPS binding native polyacrylamide gel shift (native PAGE) 
 
(A), In a 4-20% native PAGE gel stained with Coomassie blue R250 we visualized the 
interaction of purified mouse CD14 (MCD14; 10 µg) with a 2:1 molar ratio of the Ra chemotype 
of E. coli lipopolysaccharide (LPS; Sigma) in the presence of a 1:100 molar ratio of LBP:LPS 
after 1 hr incubation at 37oC (pre-incubation) as described in Materials and Methods.  A 
downshift indicates formation of the MCD14+LPS ligand bound complex. (B), The pre-
incubation time of 10 µg MCD14 with a 2:1 molar ratio of the Ra chemotype of E. coli 
lipopolysaccharide (LPS; Sigma) in the absence or presence of a 1:100 molar ratio of LBP:LPS 
was varied (30 minutes or 1 hr) to assay the length of sample incubation time required for 
complex formation.  Although we chose to standardize our pre-incubation time in subsequent 
experiments to 1 hr at 37oC, we visualized complex formation after ~5 minutes in the presence of 
LBP in similar time course experiments with mouse and human CD14 (data not shown). 
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Figure 3.3:  Native and deglycosylated human CD14 (HsCD14) purified proteins bound the Ra 
chemotype of E. coli LPS (LPS) 
 
In 4-20% native PAGE gels stained with Coomassie blue G250, the interaction of the Ra 
chemotype of E. coli LPS (LPS; Sigma) with (A), purified human CD14 (HsCD14;1 µg) and 
(B), purified human CD14 (HsCD14; 10 µg) with PNGaseF treatment (CD14 degly) were 
measured following a 1 hr pre-incubation at 37oC as described in Materials and Methods.  Where 
indicated, samples contained a 1:100 molar ratio LBP:CD14.  In both gels, a downshift was 
induced by an increased negative charge present after binding LPS indicating formation of the 
CD14-LPS ligand bound complex. 
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Figure 3.4:  Two ForteBio Octet QK traces showing the Fc fusion of human CD14 following 
protein G purification (HsCD14-Fc) is capable of binding the rough Ra chemotype of LPS from 
E. coli (E. coli LPS), smooth LPS from S. minnesota (S. minnesota LPS), and the Outer surface 
protein A (OspA) from B. burgdorferi ligands in the presence of, and often with the retention of, 
LBP.  Additionally, OspA binds near the binding site of anti-CD14 (28C5). 
 
 
In both experiments, we immobilized 0.03 M of the Fc fusion of human CD14 (HsCD14-Fc) 
onto protein A biosensors and detected ligand binding using the ForteBio Octet QK as described 
in Materials and Methods.  (A), Following a 30 min wash in PBS, we measured the ability of 
immobilized HsCD14-Fc to bind LBP and either the Ra chemotype of E. coli LPS (red), smooth 
S. minnesota LPS (blue), or the TLR2/1 ligand (OspA) from B. burgdorferi (yellow), in the 
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LBP:ligand molar ratios indicated in parenthesis, for 1.5 hrs. Using a polyclonal Goat anti-LBP 
antibody (a kind gift from Dr. Peter Tobias, The Scripps Research Institute, La Jolla, CA) for 
detection, we found LBP was retained in both LPS samples, but not with OspA.   As a control, 
LBP in the absence of ligand (pink) was not bound or retained by the HsCD14-Fc biosensor.  
(B), In this experiment we first incubated HsCD14-Fc protein A biosensors (immobilization data 
not shown) with either anti-CD14 63D3 (green) or anti-CD14 28C5 (pink) for 1.5 hrs and then 
monitored the ability of the anti-CD14 antibodies to block capture of OspA in the presence of 
LBP (at a 1:1 molar ratio with HsCD14-Fc).  Previous literature showed 63D3 is unable to block 
LPS binding, while 28C5 blocks both LPS binding and cellular activation.  Our data shows only 
28C5 was capable of blocking OspA/LBP binding, indicating OspA is bound in or near the 
region of CD14 responsible for binding LPS. 
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Figure 3.5:  Human (HsCD14) and Mouse (MCD14) Bioactivity Assay  
 
 
(A), Purified human HsCD14 (1 µg/mL) was pre-incubated with a 1:100 molar ratio LBP:CD14 
and increasing concentrations LPS for 1 h at 37oC.  Alternatively, LPS was incubated with 2% 
human serum.  (B), Similarly, purified mouse CD14 (1) was pre-incubated with a 1:100 molar 
ratio LBP:CD14 and increasing concentrations of LPS for 1 hr or overnight at 37C as described 
in Materials and Methods.  In both experiments, SW620 cells were stimulated for 6 hours with 
these preformed complexes and IL-8 was measured in culture supernatants. 
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Figure 3.6:  Initial Sparse Matrix Screen Results for Mouse CD14 (MCD14) 
 
 
We were unable to obtain crystals utilizing the published crystallization condition for Mouse 
CD14 (69)  (listed as MCD14 Published above) likely due to the use of different expression 
systems, so we conducted an initial sparse matrix crystallization screen with our purified Mouse 
CD14 (MCD14) protein using three commercially available kits (Wizard I and II from Emerald 
Biosystems and Crystal Screen I from Hampton Research) to look for single crystals.  Pictures of 
hanging drops yielding the best results from the initial screen, including crystal clusters or single 
crystals, are shown and the compositions of the commercially available reagents are indicated. 
.  
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Figure 3.7:  No diffraction quality crystals resulted from MCD14 (or HsCD14; data not shown) 
crystallization with the Ra chemotype of E. coli LPS in the presence of LBP 
 
All three hanging drop conditions are commercially available reagents Wizard I #28, Wizard I 
#30, and Wizard I #7 (Emerald Biosystems).  For this experiment, 10 mg/mL MCD14 was 
purified with PNGaseF treatment as described in Materials and Methods prior to incubation with 
the Ra chemotype of E. coli LPS and a catalytic amount of LBP (1:100 LBP:CD14) for 1 hour at 
37oC prior to setting out the crystallization tray at RT.  In all crystallization efforts with ligand 
present, phase separation or protein aggregation were predominant outcomes, resulting in a lack 
of crystals for further optimization.  The best result was obtained with Wizard I #7 showing the 
presence of four potential microcrystals. 
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CHAPTER 4: 
 
IgE and Ligand Binding Studies of Der p 2 Allergen 
 
4.1 Introduction 
 
Der p 2 induces an allergic response by acting as a structural and functional mimic of 
MD-2 in the LPS sensing pathway (Chapter 1).  Given this functional role of Der p 2, we were 
interested in determining if we could express Der p 2 using yeast display and develop an assay 
for detecting binding to LPS and TLR4.  Yeast display is a powerful technique pioneered by the 
Kranz lab to allow rapid screening of large libraries of mutants on the surface of yeast in order to 
identify mutations that lead to increased protein stability or higher ligand affinity using a high-
throughput fluorescence activated cell sorting format that circumvents the need for protein 
purification (193).  Thus, we anticipated that yeast display of Der p 2 would enable us to identify 
and characterize the residues of this protein involved in LPS and TLR4 binding.   
The yeast display system involves fusion of a protein encoding gene of interest to a gene 
encoding the yeast a-agglutinin 2 (Aga2) protein within a yeast expression vector.  Since the 
Aga2 protein inherently associates with the chromosomally encoded surface displayed Aga1 
yeast protein by disulfide bonding, the protein of interest is displayed on the surface of yeast 
(Figure 4.1).  We created two yeast display constructs in which the yeast Aga2 protein was fused 
to either the amino or carboxyl terminus of Der p 2; hereafter named N-Dp2 and C-Dp2, 
respectively.  Similarly, we constructed a C-terminal Aga2 fusion of MD-2 for comparison 
(named C-MD-2).   
Alongside our efforts, the N-terminal fusion of MD-2 (N-MD-2) was created by Dr. 
Adam Chervin and utilized by Daiva Mattis (Kranz Lab, University of Illinois, Urbana) to 
identify residues important for LPS and TLR4 binding.  Their work showed yeast displayed N-
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MD-2 is full-length, properly folded, and able to bind both biotinylated E. coli LPS and the 
purified extracellular domain of human TLR4.  Therefore, we chose to use N-MD-2 alongside 
our N-Dp2, C-Dp2, and C-MD-2 yeast display binding assays as a positive control.  We also 
used an unrelated N-terminal Aga2 fusion (N-L3) as a negative control in our studies.  L3 is a 15 
kD TCR V protein, which was kindly provided by Davia Mattis (Kranz Lab, University of 
Illinois, Urbana).   
As we will discuss in this Chapter, we were able to detect full length expression of our 
stable N-Dp2, C-Dp2, and C-MD-2 fusions on the surface of yeast.  Because of the thermal 
stability of Der p 2 discussed in Chapter 1, difficulties arose when we attempted to use thermal 
denaturation to test Der p 2 folding.   We tested the ability of our Der p 2 and MD-2 fusions to 
bind E. coli LPS and the purified extracellular domain of human TLR4 (kindly provided by 
Diana Ranoa, Tapping Lab, University of Illinois, Urbana).  Detection of TLR4 binding would 
provide additional biophysical evidence of the ability of Der p 2 to act as an adjuvant in the 
allergic arm of the MD-2/TLR4/LPS sensing pathway. 
As a second goal, we recently shifted our focus to researching the Der p 2 yeast display 
system as a rapid, cost effective, and clinically relevant method to detect and quantify levels of 
IgE in dust mite allergic patient samples.  Historically, two methods have been utilized to detect 
the level of an allergic response in an individual.  The first method, an in vivo skin-prick test, 
uses one or more allergens to the skin with a disposable tool containing fine needles, or 
alternatively, injected just below the outer dermal layer.  Usually, the allergens are placed on 
identifiable marks or in a grid, enabling a physician to identify atopic (or allergic) patients who 
develop a raised white patch and surrounding redness from blood vessel dilation typical of a 
“wheal and flare” response to the appropriate allergen.  Histamine and saline are applied as 
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positive and negative controls for comparison and the physician records the allergic response on 
a 0-5 scale as compared to histamine.  Although this in vivo method allows for rapid detection in 
less than an hour, its drawbacks include the limits of quantitation using a 0-5 scale, the 
requirement of highly pure allergens, and the inaccurate results obtained if the patient is taking 
anti-allergy medications or has a skin condition capable of interfering with detection.  Although 
this method is predictive, skin-prick tests do have a higher false-positive rate than other test 
methods (194). 
The second commonly used in vitro method for diagnosing allergy involves detection of 
immunoglobulin E (IgE) antibodies specific to an allergen.  As discussed in Chapter 1, IgE 
mediates the human allergic response by binding both the allergen and an FcεRI receptor that is 
primarily expressed on the surface of mast cells and basophils (~100,000 receptors per cell) in 
skin, tissue near mucosal layers and gastrointestinal sites, causing the release of histamine and 
other mediators capable of inducing allergic symptoms in affected patients.  Since the 
concentration of serum IgE is less than 1 g/mL and it binds with high affinity (>10-9 M) to its 
receptor FceRI, IgE is the most difficult antibody to detect in human fluids (195).   
Various forms of in vitro IgE detection systems have been created by Thermo Scientific.  
Since the 1960s, the first IgE detection radioallergosorbent test (RAST) has been used 
nationwide in commercial clinical reference labs (196).  In RAST, patient serum is applied to a 
paper disk or polyurethane cap (RAST-CAP) containing an immobilized allergen for three hours.  
Any IgE from the serum that binds is detected using a radioactively labeled anti-human IgE 
antibody incubated with the immobilized allergen for 16-30 hours prior to detection.  Thus, this 
test is neither rapid nor automated, but it produces a quantitative result by comparing the 
resulting radioactivity to an anti-birch antibody response to birch allergen standard.  The 
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measurements are read in RAST units per milliliter (RU/mL), and results are grouped into 
Classes 0-4.  One of the major benefits of RAST testing is the lack of patient risk for 
anaphylactic shock since the allergen is not being introduced in vivo.  Also, allergens can be 
coarsely purified or homogenized prior to immobilization, so this system does not require highly 
purified allergens.  Additionally, patients taking anti-allergy medications at the time of the test or 
those with skin conditions can still obtain test results without interference with the testing 
method.  Finally, this standardized quantitation and classification system allows for a more 
straightforward comparison between patients.  Improvements to this test have been made 
including the use of an enzyme linked anti-human IgE antibody that provides a colormetric result 
when a color changing substrate is applied in an enzyme immunoassay (EIA) format or the use 
of a fluorescently-labeled anti-human IgE antibody for detection. 
A second generation, fully automated allergosorbent system called ImmunoCAP was also 
produced by Thermo Scientific and is now considered the standard clinical method of IgE 
detection by the National Institutes of Health (197).  Much like RAST, ImmunoCAP uses an 
immobilized allergen to bind allergen specific IgE from patient sera and detects binding via a 
fluorescently-labeled anti-human IgE antibody.  However, in ImmunoCAP testing the allergen is 
immobilized to a highly-branched, hydrophilic, cellulose derivative in a solid phase instead of a 
two dimensional paper or solid support, leading to the capture of more allergens per test and 
increasing assay sensitivity.  IgE measurements are quantified in this system in international 
units per liter (kU/L).  These values are determined by comparison of the measurement with a 
standard created by the World Health Organization by pooling nine donor serum samples 
together at a potency of 5,000 IU (WHO Reference Reagent NIBSC 75/502).  Similarly, a house 
dust mite D. pteronyssinus extract is available with a potency of 100,000 IU (WHO Reference 
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Reagent NIBSC 82/518).  The quantified results correspond to Classes 0-6, where Class 0 (<0.35 
kU/L) is considered negative, Class 1 (0.35-0.69 kU/L) is very low, Class 2 (0.70-3.49 kU/L) is 
low, Class 3 (3.5-17.49 kU/L) is moderate, Class 4 (17.5-49.99) is high, Class 5 (50-100 kU/L) is 
very high and Class 6 (>100 kU/L) is at or above the limit of detection.  As mentioned before, 
the sensitivity of ImmunoCAP testing is much higher than that achieved with RAST.  In fact, the 
RAST Classes 0-4 correspond to the 0.35-17.5 kU/L detection range of ImmunoCAP (198).  In a 
study of 39 adults, the ImmunoCAP system had high sensitivity (94%) and specificity (100%) in 
utilizing IgE to detect for the 23 patients suffering from respiratory allergies (198). 
A major limitation of the ImmunoCAP method is the inability to test more than one 
allergen specifically in each screen, so testing can be expensive.  To overcome this limitation, 
Thermo Scientific recently created the ImmunoCAP immuno solid-phase allergy chip (Immuno 
CAP ISAC).  Immuno CAP ISAC uses the same technology as ImmunoCAP, but screens a panel 
of 103 allergens in a multi-array chip format, enabling detection of more than one allergy 
sensitization and the identification of cross-reaction in a patient sample at the same time (199).  
Similarly, physicians can now probe beyond whole dust mite homogenates present in 
ImmunoCAP and ImmunoCAP ISAC to detect serum IgE bound to individual allergenic 
proteins, like Der p 2, using a more limited panel of purified allergens called the ImmunoCAP 
highly refined (ImmunoCAP HR) test.   
An additional limitation of all ImmunoCAP methods described previously is the need to 
purchase the proprietary ImmunoCAP machine and/or ImmunoCAP ISAC chip required to run 
the test, which is an added expense in the clinical setting.  Alternatively, clinicians can ship 
patient samples to a commercial clinical laboratory for ImmunoCAP testing, resulting in a longer 
wait time for results.  In an attempt to overcome the wait time limitation, Thermo Scientific 
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recently developed a rapid ImmunoCAP asthma/rhinitis test, allowing the detection of serum IgE 
specific for a panel of 10 allergens, not including Der p 2, in patient blood applied to a single-use 
testing strip.  Although the test strips still have to be purchased and the result is simply 
qualitative, physicians can detect IgE specific for the 10 allergens in 20 minutes. 
In this Chapter, we utilized our yeast displayed Der p 2 as a novel method to detect IgE 
from dust mite allergic and non-allergic patient serum and plasma samples using flow 
cytometery.  Since flow cytometry is actively utilized in research and clinical laboratories, our 
technique would overcome the costly requirement for purchasing proprietary equipment to 
conduct IgE detection.   A simple extension of our methodology could use mutant forms of Der p 
2 in our yeast display system to detect IgE epitopes specific for an individual patient.  This same 
type of detailed analysis of Der p 2 interactions with IgE is not possible with the RAST, 
ImmunoCAP, ImmunoCAP HR, or ImmunoCAP ISAC methods, as they provide simple 
quantitation of IgE binding, so our flow cytometry based method  would complement, not 
replace, existing in vitro detection systems.  In this Chapter, we offer proof-of-concept by 
successfully displaying Der p 2 on the surface of S. cerevisiae and quantitatively measuring the 
binding of IgE from patient serum and samples using our novel in vitro, flow cytometry-based 
IgE detection system. 
 
4.2 Materials and methods 
 
4.2.1 Reagents 
 The yeast display vector pCT302 and two additional N-terminal Aga2 fusions containing 
MD-2 and a V-TCR called L3 were kindly provided by Daiva Mattis (Kranz Lab, University of 
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Illinois, Urbana-Champaign).  The Y10 yeast display vector was kindly provided by Dr. David 
Aggen (Kranz lab, University of Illinois Urbana-Champaign).  Additional fluorescent reagents, 
antibodies, and purified proteins are described along with methods below.  Media and reagents 
utilized in this work for subcloning were previously described in Chapter 2.  Likewise, we 
purchased chemically competent E. coli DH5α cells and LB-agar plates containing 100 g/mL 
ampicillin from the University of Illinois at Urbana-Champaign (UIUC) cell Media Facility 
(kindly produced by Dr. Sandra McMasters).   EBY100 cells grown in YPD media (yeast extract 
10 g/L; peptone 20 g/L, and dextrose 20 g/L) were kindly provided by Sheena Smith and Daiva 
Mattis (Kranz lab, University of Illinois, Urbana).   Two forms of minimal media plus amino 
acids were used for yeast cultures.  SD-CAA (SD media) contained dextrose (20g/L), yeast 
nitrogen base without amino acids (7 g/L), 19 mM Na2HPO4, 36 mM NaH2PO4, and casamino 
acids (5 g/L).  SG-CAA (SG media) used the same recipe for preparation except dextrose was 
replaced with galactose (20 g/L). 
   
4.2.2 Yeast Display of Der p 2 and MD-2  
  To create the N-terminal fusion of Der p 2 (N-Dp2), we ordered synthetic, codon 
optimized DNA (Genescript) encoding a NheI site, aa 18-146 of Der p 2 (omitting its leader 
sequence), a c-Myc epitope tag (EQKLISEEDL), two stop codons (TGA and TAA), and an XhoI 
site.  The yeast display vector pCT302 was restriction enzyme digested with NheI and XhoI and 
treated with calf alkaline phosphatase (NEB).  Vector digests were visualized on a 2% agarose 
gel with a 1 kB DNA ladder (Promega) using 6xDNA loading dye.  The pCT302 yeast display 
vector contains a galactose inducible promotor (GAL1) prior to an EcoRI restriction site, 
upstream of DNA encoding Aga2, followed by the influenza hemagglutinin epitope tag HA 
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(YPYDVPDYA), a Gly-Ser linker region and a NheI restriction site.  We ligated the N-Dp2 
insert into pCT302 using T4 DNA ligase (Invitrogen), and after transformation of E.coli DH5α 
competent cells, we grew transformants on LB-Amp plates overnight at 37oC.  We placed single 
colonies in 5 mL LB-Amp cultures overnight 37oC with shaking, and harvested DNA from each 
culture by miniprep (Qiagen).  DNA sequencing (UIUC Biotechnology Center) and restriction 
enzyme digestion with EcoRI and NdeI followed by agarose gel electrophoresis were two 
methods used to confirm subcloning.    
 Next, we transformed yeast cultures with our sequenced pCT302 N-Dp2 vector.  Multiple 
3 mL cultures of 100 L EBY100 yeast were grown in YPD media without antibiotics in a 30oC 
incubator with shaking, overnight, and then transformed with 1, 5, or 10 L N-Dp2 pCT302 
DNA by LiOAc heat shock.  Afterwards, transformed EBY100 yeast were plated on yeast media 
containing dextrose (SD) plates without antibiotics and incubated at 30oC for 3 days.  After 
colony growth, single EBY100 transformed colonies were picked and grown in 3 mL cultures of 
SD media with 100 g/mL penicillin/streptomycin (Gibco) in a 30oC incubator with shaking.  
DNA extraction was completed using zymolase digestion of the yeast cell wall and alkaline lysis 
via Zymoprep Yeast Plasmid Miniprep II (Zymo Research).  DNA sequencing (UIUC 
Biotechnology Center) and restriction enzyme digestion with EcoRI and NdeI followed by 
agarose gel electrophoresis were used to confirm yeast transformation.  Stocks of N-Dp2 
transformed EBY100 yeast were frozen in media containing 25% glycerol.  Unless indicated, 
transformed yeast were inoculated into SD media at 30oC from frozen stocks.  Expression of the 
N-Dp2 protein from EBY100 was induced by growing the cells in yeast media containing 
galactose (SG) at 20oC for 48 hours. 
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 Similarly, DNA encoding C-Dp2 and C-MD-2 were purchased (Genescript) and encoded 
an EcoRI site, the Aga2 signal peptide (aa 1-18), Der p 2 or MD-2, a c-Myc epitope tag 
(EQKLISEEDL), and an Nde I site.  Using the same subcloning method described in this 
Chapter, the synthetic DNA was ligated into a Y10 vector.  The Y10 yeast display vector was 
previously created from pCT302 by rearranging the orientation of the Aga2 fusion onto the C-
terminus of the target protein (kindly provided by Dr. David Aggen, Kranz lab, University of 
Illinois, Urbana).  Y10 has an NdeI site, followed by Aga2, an HA epitope tag (YPYDVPDYA), 
a stop codon, and an XhoI/BglII site.  Following ligation and transformation into Y10, E. coli 
cells were used for amplification, sequencing was completed, EBY100 yeast were transformed 
and the final transfectants were sequenced as described above for the N-terminal fusion.  
Likewise, stocks of C-Dp2 and C-MD-2 transformed EBY100 yeast were frozen in media 
containing 25% glycerol.  Expression of the C-Dp2 and C-MD-2 protein from EBY100 was 
induced by growing the cells in yeast media containing 2% galactose (SG) at 20oC for 48 hours 
prior to flow cytometry. 
 
4.2.3 Detection of Yeast Displayed Der p 2 and MD-2 
 We stained 1x106 N-Dp2, C-Dp2, and C-MD-2 transformed EBY100 yeast cells after 
induction in SG media at 20oC with shaking for 48 hours followed by washing.  Each washing 
stage noted below involved one dilution and two wash steps with 1 mL PBS containing 0.5% 
bovine BSA (Sigma), followed by yeast cell pelleting via centrifugation at 3,000 rpm, 3 min, 
4oC, and vacuum aspiration of wash reagent.  Yeast were washed and stained with mouse IgG1 
anti-HA antibody (HA.11 Clone 16B12, MMS-101R, Covance) and chicken anti-c-Myc 
antibody (A21281; Invitrogen) incubated in 1:50 dilutions at 4oC for 1 hr.  To probe for Der p 2 
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on the cell surface, we used a variety of monoclonal mouse IgG1 anti-Der p 2 antibodies from 
Indoor Biotechnologies at 1:100 dilution including DpX (MA-DPX), 1D8 (MA-1D8-1), 
biotinylated-7A1 (MA-B-7A1), and 10E11 (MA-10E11), and an anti-Der f 2 antibody (13A4) 
that was previously shown to cross react with Der p 2 in literature.  To probe for MD-2, we used 
two monoclonal anti-human MD-2 antibodies called 4H1 (HM2243) and 18H10 (HM2245) from 
Hycult at a 1:100 dilution.  Cells were washed following primary antibody staining.  Secondary 
antibodies used at 1:200 dilution include the Alexa Fluor 647 conjugated goat anti-mouse (#A-
21237; Invitrogen) and APC conjugated goat anti-chicken (A21449; Invitrogen) antibodies.  To 
detect biotin, Alexa Fluor 647 conjugated streptavidin (S32357; Invitrogen) was used at a 1:200 
dilution.  All cells were washed and resuspended in 200 L 1xPBS for flow cytometry detection.  
In all flow cytometry experiments, fluorescence was detected with an Accuri C6 flow cytometer 
where we gated on a positive population of FCS vs. SSC live cells, unless gating parameters are 
otherwise indicated, and captured 10,000 events using a slow flow rate with a detection filter of 8 
 size limit. 
 
4.2.4 Thermal Denaturation of Yeast Displayed Der p 2 
 We stained 1x106 EBY100 transfected N-Dp2 or C-Dp2 cells after induction in SG media 
at 20oC for 48 hours.  Cells were washed as previously described.  Each eppindorf tube contained 
a 1:100 dilution of an anti-Der p 2 (DpX, 1D8, biotinylated 7A1, or 10E11) or anti-Der f 2 
antibody (13A4).  Yeast were incubated  at the temperature indicated in the figure for 1 hour, 
followed by washing and resuspension in 200 L 1xPBS prior to flow cytometry detection as 
previously described. 
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4.2.5 LPS Binding Studies 
 To probe for LPS binding, we incubated biotinylated ultrapure E. coli O111:B4 LPS EB-
Biotin from InvivoGen (EB-LPS; catalogue #tlrl-bblps) or a non-biotinylated precursor form of 
ultrapure E. coli O111:B4 LPS (O-LPS; catalogue #tlrl-pelps) with 1x106 EBY100 transformed 
N-Dp2, C-Dp2, N-MD-2, C-MD-2, N-L3, or empty Y10 vector  for 1 hour at 4oC.  Following 
washing, we detected bound EB-LPS using Alexa Fluor 647 conjugated streptavidin (S32357; 
Invitrogen) at a 1:200 dilution incubated for 1 hour at 4oC.  To detect bound O-LPS, we used a 
serotype specific monoclonal antibody from Hycult (mouse anti-core; WN1222-5) incubated 30 
minutes to 1 hour at 4oC.  After a final wash and resuspension in 200 L 1xPBS, we detected 
fluorescence using flow cytometry as previously described.   At times, we preincubated mouse 
(MCD14) or human soluble CD14 (HsCD14) described in Chapters 2 and 3 at 37oC with 
biotinylated or non-biotinylated LPS (molar ratios indicated), prior to addition to transformed 
yeast cells. 
 
4.2.6 TLR4 Binding Studies 
 We used a purified extracellular domain of human TLR4 (aa 27-527) kindly provided by 
Diana Ranoa (Tapping Lab, University of Illinois, Urbana) in our flow cytometry binding 
studies.  1x106 EBY100 transformed N-Dp2, C-Dp2, N-MD-2, C-MD-2, N-L3, or empty Y10 
vector were mixed with the TLR4 protein for 1 hour at RT.  Following washing as previously 
described, mouse IgG2a anti-Human CD284/TLR4 antibody (HTA125; EBioscience) at a 1:100 
dilution was utilized.  Following washing as previously described, the AlexaFluor 647 
103 
 
conjugated goat anti-mouse secondary at a 1:100 dilution was used for detection.  Following 
washing, the cells were resuspended in 200 L 1xPBS for flow cytometry detection as 
previously described.  
 
4.2.7 IgE Binding Studies 
 We purchased dust mite allergic and non-allergic patient serum and plasma samples from 
Plasma Lab International.  Following washing, we incubated 100 L of each sample (without or 
with dilution as indicated in the figure) with 1x106 EBY100 transformed N-Dp2 and C-Dp2 
cells.  To detect human IgE, we used biotin-labeled affinity purified Goat anti-Human IgE (16-
10-04; KPL) antibody at a 1:100 dilution.  Following washing we detected biotin using Alexa 
Fluor 647 conjugated streptavidin (S32357; Invitrogen) at a 1:200 dilution.  Following washing 
and final resuspension in 200 L 1xPBS, flow cytometry was utilized to produce binding 
profiles.  Binding curves with non-linear least squares fitting were created using GraphPad Prism 
6. 
 
4.3 Results 
 
 
4.3.1 Yeast Display of Der p 2and MD-2 
 
 Initially, we chose to display an N-terminal fusion of Der p 2 (N-Dp2) on the surface of 
S. cerevisiae EBY100 yeast using the pCT302 yeast display vector (Figure 4.1 A).  Following 
subcloning and sequencing to confirm proper insertion of DNA into the NheI and XhoI sites on 
pCT302, as described in the Materials and Methods section in this Chapter, we induced 
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expression of the protein using media supplemented with galactose.  This induction makes use of 
the GAL1 promotor that is incorporated in the pCT302 vector upstream of our Der p 2 construct.  
As described previously, we obtained N-MD-2 and N-L3 from the Kranz lab for use as controls 
in our flow cytometry experiments. 
 Hakkart and colleagues discovered that addition of even one Ala amino acid to the N-
terminus of recombinant Der p 2, expressed as a secreted protein in S. cerevisiae yeast, both 
eliminated the ability of the anti-Der p 2 monoclonal antibody 10E11 to bind and decreased IgE 
reactivity for 14 of 16 patient sera tested by RAST (200).  Because we recognized that the Aga2 
fusion placement may alter the expression or function of our Der p 2 protein, we chose to create 
a C-terminal fusion of Der p 2 (C-Dp2).  A C-terminal MD-2 fusion (C-MD-2) was also created 
as a control for our studies (Figure 4.1 B).  These constructs utilized the Y10 vector (a derivative 
of the pCT302 vector) which enables C-terminal Aga2 fusion protein production under the same 
galactose inducible promoter.   
 To confirm that our N-Dp2, C-Dp2, and C-MD-2 constructs were displayed as full-length 
Aga2 fusions on the cell surface, we stained the cells with anti-HA and anti-c-Myc to detect the 
HA and c-Myc epitope tags.   All of our flow cytometry experiments utilized secondary antibody 
detection of the unrelated protein N-L3 (grey; spacefilled) to determine the background detection 
of our flow cytometery system.  For N-Dp2, the HA and c-Myc epitope tags were detected 
(orange and lime, respectively) (Figure 4.2 A).  Likewise, the HA tag was detected from the C-
terminal fusions C-Dp2 and C-MD-2 (red and blue, respectively) (Figure 4.2 B).  As expected, 
our N-MD-2 (light blue) and N-L3 (purple) controls were expressed, and our empty Y10 vector 
(green) was not detected using anti-HA because it does not contain the HA epitope tag (Figure 
4.2B). 
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 We wanted to confirm the N-MD-2 protein and C-MD-2 proteins we were producing 
were capable of being recognized by anti-MD-2 antibodies.  Previous thermal denaturation work 
conducted by Daiva Mattis in the Kranz lab showed the anti-MD-2 antibody 18H10 may 
recognize a conformational epitope; whereas, binding of the anti-MD-2 antibody 4H1 was 
unaffected by changes in temperature, so it may recognize a linear epitope (unpublished).  Using 
flow cytometry, we verified binding of the 18H10 antibody to yeast displayed N-MD-2, 
suggesting that this protein is folded (Figure 4.3 A).  As expected, anti-MD-2 18H10 binding to 
the either N-L3 (purple) or N-Dp2 (orange) proteins was not detected.  Similarly, staining of C-
MD-2 shows 18H10 binding (light blue), indicating the C-terminal fusion we created is also 
properly folded upon display (Figure 4.3 B). 
 Multiple anti-Der p 2 monoclonal antibodies (DpX, 1D8, 7A1, and 10E11) were used to 
detect our N and C-terminal fusions of Der p 2 on the surface of yeast.  Previously, Hakkaart and 
colleagues conducted mutagenesis and deletion studies of secreted recombinant Der p 2 
expressed in S. cerevisea and showed that the epitope of the DpX antibody resides within aa 65-
80 (9).  The binding of the 7A1 antibody is affected by mutations in amino acid residues 22-26, 
45-48, 88-90 (201), and Lys 100 (202).  Both DpX and 7A1 anti-Der p 2 antibodies were found 
to cross react with the homologous group II allergen Der f 2 (115).   Similarly, anti-Der f 2 
antibody 13A4 was reported to be slightly cross reactive to Der p 2 (115), and binding of this 
antibody was abolished when Der p 2 Lys 100 was mutated (202).  We included this anti-Der f 2 
antibody in our examination of yeast displayed Der p 2 because epitope mapping NMR studies 
showed 13A4 binding depends upon the conformation of Der f 2 (203), so we hypothesized 
13A4 binding may support the conclusion that Der p 2 is properly folded upon display.  
Additionally, as mentioned previously, anti-Der p 2 antibody 10E11 is capable of differentiating 
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between Der p 2 with and without one additional amino acid on the N-terminus.  Mutagenesis of 
Der p 2 aa 22-26, 45-48,  67 and 69, and 73-78 decreased binding of 10E11, which may indicate 
10E11 recognizes a conformationally dependent epitope that is only formed upon proper folding 
(201).  
 Anti-Der p 2 antibody 1D8 was able to bind N-Dp2 (orange), but, as expected, did not 
bind N-MD-2 (light blue) or N-L3 (purple) non-specifically (Figure 4.4 A).  1 D8 was also able 
to bind C-Dp2 (red) (Figure 4.4 B).  In the same experiment, we were encouraged to see C-Dp2 
recognition by 10E11 (pink) without detectable binding to N-Dp2 (green) (Figure 4.4 B).  We 
also tested the ability of both Der p 2 constructs to bind DpX and 7A1.  N-Dp2 (data not shown) 
and C-Dp2 (orange) was detected by DpX, similar to detection using 1D8 (green) (Figure 4.4 
C).  Similarly, we were able to detect 7A1 binding to both fusions (data not shown). 
 As a whole, this data indicates we properly constructed a yeast display system that 
expresses Der p 2 containing linear and possibly conformational epitopes for antibody 
recognition.  We also tested N-Dp2 and C-Dp2 folding using denaturation studies (204).  We 
screened the loss of antibody binding upon Der p 2 thermal denaturation for each anti Der p 2 
antibody (DpX, 1D8, biotinylated 7A1, and 10E11) as described in Materials and Methods.  All 
of the antibodies capable of binding N-Dp2 and C-Dp2 still bound both proteins upon heating to 
100oC.  For example, after heating to 100oC we could detect 1D8 binding to N-Dp2 (Figure 4.5 
A).  We also screened 10E11 binding to C-Dp2 (Figure 4.5 B) and N-Dp2 (Figure 4.5 C), and 
observed similar profiles at all temperatures tested.  Finally, we screened the anti-Der f 2 
antibody 13A4 and found little to no detection of binding (Figure 4.5 D).  As mentioned 
previously, Der p 2 is highly thermostable (121) and is only mostly denatured after a 60 minute 
incubation at 140oC (205), but the viability of the yeast display scaffold has only been tested to 
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~90oC (204).  Since this thermal denaturation method does not appear to denature Der p 2, it is 
difficult to confirm proper folding.  However, both N-Dp2 and C-Dp2 are properly recognized 
by a variety of anti-Der p 2 antibodies. 
 
4.3.2 Yeast Displayed Der p 2 and MD-2 Bind LPS 
 We tested the ability of Der p 2 and MD-2 to bind LPS by using biotinylated E. coli 
O111:B4 (EB-LPS) as described in Materials and Methods.  Titration studies of EB-LPS with 
the N-terminal Aga2 fusions of MD-2 and Der p 2 indicated binding, but a minor background 
level of interaction with the L3 negative control was also detected (Figure 4.6).  We did not 
expect to see detectable binding of EB-LPS to the N-terminal Aga2 fusion of L3, so we decided 
to screen EB-LPS binding to a panel of unrelated N-terminal Aga2 fusion yeast displayed 
proteins (kindly provided by Sheena Smith and Daiva Mattis, Kranz lab, University of Illinois, 
Urbana).  Proteins I, W, and A are all stable, high stability and high affinity engineered 29 kD 
single chain T cell receptor V-Vα Aga2 fusions, which differ in their Vs.  Protein K is the 
single chain variable region of an antibody targeting V and Protein D is a human T cell receptor 
V.  Both are approximately 13 kD and are fused to Aga2.  Protein C is a 25 kD co-stimulatory 
molecule expressed as an Aga2 fusion.   Binding profiles for each are shown in Figure 4.6.  
Proteins K, C, and W all showed interactions with EB-LPS to a greater extent than our N-L3 
negative control.  All of the unrelated proteins indicated binding to EB-LPS to a lesser extent 
than N-MD-2, and most of the unrelated proteins indicated lower detection of EB-LPS binding 
than N-Dp2.  Further analysis would require additional replicates of this experiment, with the 
addition of our C-terminal Der p 2 and MD-2 fusions. 
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 We also tested non-biotinylated E. coli O111:B4 (O-LPS) binding to both fusions of Der 
p 2 and MD-2 using a serotype specific antibody that binds the core polysaccharide region of 
LPS as described in Materials and Methods, as a way to confirm that protein-LPS interactions 
were not disrupted or unnaturally aided by biotinylation of the ligand.  N-MD-2 (light blue), C-
MD-2 (dark blue), C-Dp2 (red), and N-Dp2 (orange) all indicated binding to O-LPS (Figure 4.6 
B).  We also detected O-LPS binding to yeast containing the empty Y10 vector (green) and N-L3 
(purple).  Dr. Adam Chervin in the Kranz lab showed that addition of our purified human 
HsCD14 protein reduced EB-LPS binding to an unrelated control protein while not affecting 
binding of EB-LPS to N-MD-2 (unpublished).  We tested the ability of CD14 to reduce binding 
to N-L3 by pre-incubating a 2:1 molar ratio of human soluble CD14 (HsCD14) or mouse CD14 
(data not shown) with O-LPS for 1 hr at 37oC before incubation with our yeast fusions.  CD14 
decreased O-LPS binding to C-Dp2 (red to pink) and N-Dp2 (orange to maroon) (Figure 4.6 C).  
Similar to the reduction of LPS binding to an unrelated control in Dr. Chervin’s work, we also 
observed a reduction of O-LPS binding to our unrelated N-L3 control (dark purple to light 
purple) and our empty Y10 vector yeast cells (dark green to lime).  In other LPS binding studies, 
we added a catalytic amount of purified lipopolysaccharide binding protein (LBP) (kindly 
provided by Dr. Jerrold Weiss, University of Iowa).  As described in Chapter 1, LBP 
catalytically loads CD14 with LPS, enabling LPS delivery to the hydrophobic pocket of MD-2 in 
the LPS sensing cascade.  However, in our yeast display system, addition of LBP did not 
increase the level of EB-LPS binding we detected (data not shown). 
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4.3.3 Yeast Displayed MD-2, but not Der p 2, bind TLR4 
 
 We used flow cytometry to detect the ability of our N and C-terminal Aga2 fusions to 
bind purified human TLR4.  As described in Chapter 1, human TLR4 interacts with MD-2 and 
upon ligand binding forms a heterodimeric complex with LPS bound to the hydrophobic binding 
pocket of MD-2.  Since Der p 2 has structural similarity to MD-2, the current hypothesis is that 
Der p 2 may interact directly with TLR4, as supported by pull down data from Trompette and 
colleagues (122).  In our data, the N-terminal fusion of MD-2 exhibited binding to human TLR4 
at two different concentrations of TLR4 (dark and light blue), but N-Dp2 did not show any 
detectable level of binding at either concentration of TLR4 (orange and yellow) (Figure 4.7 A).  
Similarly, C-MD-2 exhibited binding to purified human TLR4 (dark blue), but in this and 
replicate experiments, C-Dp2 did not bind TLR4 (red) (Figure 4.7 B). 
 
 
4.3.4 Detection of Anti-Der p 2 IgE in Human Serum and Plasma Using Yeast Display 
 We studied the ability of C-Dp2 to bind IgE from a Der p 2 specific IgE Class 0 (0.02 
kU/L) non-allergic patient serum sample and a Class 5 (67.3 kU/L) allergic patient sample, as 
measured by ImmunoCAP.  Detection of IgE in patient samples utilized a biotin conjugated anti-
Human IgE antibody, which was detected with streptavidin conjugated Alexa Fluor 647.  As 
expected, we did not detect IgE binding to C-Dp2 in the non-allergic patient sample (Figure 4.8 
A), but C-Dp2 readily detected IgE from the allergic patient serum sample (Figure 4.8 B).  As 
the level of IgE decreased, through dilution of the serum sample, the fluorescence signal also 
decreased in a titratable manner (Figure 4.8 C).  Using this yeast display assay, the limit of 
detection for IgE in patient serum fell between 0.58 and 1.17 kU/L.  The histogram for the 1.17 
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kU/L sample exhibited a slight tail indicating detectable binding above the N-L3 negative control 
(red) (Figure 4.8 B). 
 We wanted to make sure that the fibrinogen and clotting factors present in patient plasma 
would not interfere with IgE detection in our system.  Therefore, we titrated a patient plasma 
sample containing the highest ImmunoCAP classification (Class 6) of Der p 2 specific IgE 
(238.09 kU/L) and assessed binding to N-Dp2 and C-Dp2.  Binding profiles were created by 
plotting triplicate relative fluorescence data of IgE binding in our system versus the ImmunoCAP 
level of IgE in the each sequential sample dilution.  The level of IgE binding to N-Dp2 saturated 
near 119.05 kU/L (dark blue) and the limit of detection fell between 0.93 kU/L (sky blue) and 
0.47 kU/L (black) (Figure 4.9A).  At the same concentrations of IgE, binding to our C-Dp2 did 
not saturate even when exposed to 238.09 kU/L IgE and the limit of detection fell near 0.93 
kU/L (sky blue) (Figure 4.9B). 
 Since the above assays rely upon theoretical ImmunoCAP numbers obtained from diluted 
serum and plasma, we assayed our yeast display system using multiple patient plasma samples 
with a range of ImmunoCAP values for Der p 2 specific IgE.  Each sample is designated by a 
one or two letter label followed by an ImmunoCAP value of IgE specific to D. pteronyssinus 
dust mite homogenate (DPT) and an ImmunoCAP value of IgE specific to Der p 2.  We included 
one patient sample as a control (GM 42.5 kU/L and 0.01 kU/L), because, although it was positive 
for DPT, it was negative for Der p 2 IgE (dark blue) (Figures 4.10A and B).  All of the other 
samples A through G were positive for DPT and Der p 2.  For example, plasma A had 1.07 kU/L 
DPT and 0.79 kU/L Der p 2 (purple) (Figures 4.10A and B).  Multiple patient samples on N-
Dp2 produced a binding curve that is nearly saturating for plasma G used in the previous titration 
studies (Figure 4.9A).  Samples were also screened against C-Dp2 (Figure 4.10B), and similar 
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to the C-Dp2 titration with plasma G (Figure 4.9B), we did not observe saturation of the 
fluorescence signal.  Importantly, all of the IgE specific Der p 2 detected in plasma A-G samples 
by the ImmunoCAP system, also had detectable fluorescence in our system.  Moreover, there is a 
good correlation between the ImmunoCAP values and the relative level of fluorescence in our 
system.  Both N-Dp2 and C-Dp2 detection systems had a similar detection limit near the plasma 
A sample (0.79 kU/L), which is near the limit of detection of the ImmunoCAP system (0.35 
kU/L).  Thus, the yeast display system appears to be capable of identifying patients with allergies 
to Der p 2 just as well as the clinically accepted ImmunoCAP system.     
 
4.4 Discussion 
 
 We were able to successfully create N-terminal and C-terminal Aga2 fusions of Der p 2, 
and for comparision purposes, a C-terminal Aga2 fusion of MD-2.  Detection of the HA and c-
Myc epitope tags allowed us to determine that N-Dp2, C-Dp2, and C-MD-2 are all expressed as 
a full-length, stable proteins on the surface of yeast.  Conformationally dependent anti-MD-2 
antibody 18H10 was able to detect C-MD-2, suggesting proper folding of this protein upon 
display.  Multiple anti-Der p 2 antibodies (DpX, 1D8, and 7A1) bound both N-Dp2 and C-Dp2 
showing that yeast display did not disrupt these antibody epitopes.  Anti-Der f 2 antibody 13A4 
is a conformational antibody in the Der f 2 system and was previously reported to contain slight 
cross-reactivity with Der p 2 as discussed previously in this Chapter.  13A4 produced little to no 
detectable binding to N-Dp2 or C-Dp2.  N-Dp2 was not detected using anti-Der p 2 10E11, but 
C-Dp2 was detected as expected.  Anti-Der p 2 antibody 10E11 may be a measure of proper 
conformation or the epitope recognized by this antibody may be disrupted by changes to the N-
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terminus of the protein.  Thus, we have produced two forms of full-length, stable recombinant 
Der p 2 in a yeast display format that appear to be properly folded but without unequivocal 
evidence of proper folding. 
 We probed the functional homology of Der p 2 and MD-2 using flow cytometry to detect 
binding of E. coli LPS and purified human TLR4.  LPS binding to Der p 2 is indicated, 
regardless of the presence of biotin, though we do not detect purified human TLR4 binding.  We 
do not have evidence suggesting soluble human CD14 or purified LBP (data not shown) are 
actively delivering LPS to Der p 2 in our experiments.  Rather, it appears that soluble CD14 is 
reducing the amount of LPS associated with yeast expressing either Der p 2, the negative control 
L3, or the vector alone.  Our negative control panel suggests LPS is able to associate with other 
Aga2 containing yeast displayed proteins.  When we added CD14 to our negative control panel, 
we also saw reduced detection of LPS binding (data not shown).  Thus, CD14 may be acting 
more as a sink for LPS, instead of actively shuttling LPS to Der p 2.  The one hour 37oC pre-
incubation time that we are using to associate human HsCD14 and LPS prior to addition of yeast 
may also be insufficient for the formation of CD14-LPS complexes.  Our native PAGE gel shift 
efforts, like those described in Chapter 2, have shown that the addition of LBP enables CD14-
LPS complex formation in one hour, but the lack of LBP limits the completeness of CD14-LPS 
complexation in that same time frame, suggesting extended incubation time is needed for 
samples lacking LBP.  However, overnight incubation of HsCD14 at 37oC decreased IL-8 
production in our bioactivity assays (data not shown).  So, repetition of LPS binding studies 
using the yeast display system may require a more prolonged incubation of LPS and human 
HsCD14, ideally in the presence of a catalytic amount of LBP, to enable production of CD14-
LPS complexes prior to incubation with yeast displayed Der p 2. 
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  Our thermal denaturation studies reaffirm Der p 2 is highly thermostable.  Previous work 
showed Der p 2 proteins are also insensitive to changes in pH or denaturation with 6M guanidine 
HCl, and that reduction of Der p 2 reduces detection of IgE binding, suggesting that a portion of 
IgE epitopes may be conformationally dependent (121).  Previous work screening dust mite 
allergic patient sera with fragments of Der p 2 expressed as glutathione S-transferase fusions 
showed detectable binding of IgE in only 15 of the 57 patient serum samples tested, suggesting 
the majority of IgE epitopes are not linear (206).  Likewise, applying dust mite allergic patient 
sera to overlapping, short synthetic peptides covering the sequence of Der p 2, which were 
coupled to sepharose, showed detection of IgE binding only when the peptide included aa 1-15 
or aa 65-78 (207).   
 The fact that we were able to use our yeast display N- and C-terminal Der p 2 Aga2 
fusions to detect IgE from allergic patient serum and plasma samples, we have provided 
additional support that our N-Dp2 and C-Dp2 Aga2 fusions are properly folded on the surface of 
yeast.  Our binding curves measure total binding of Der p 2 specific IgE which includes both 
linear and conformational epitopes.  The C-Dp2 Aga2 fusion was not saturated at the highest 
dose of IgE, suggesting that it has the ability to bind additional IgE compared to the N-Dp2 
fusion.  Thus, the C-Dp2 Aga2 fusion may be binding additional IgE to conformational epitopes 
that are not available on N-Dp2 or are disrupted by the presence of Aga2 at the N-terminus. 
 Most importantly, we have created a novel in vitro IgE detection method utilizing flow 
cytometric measurements of yeast particles in a quantitative format that can be useful in clinical 
or research settings.  Our predictive capacity is similar to ImmunoCAP in that all of the samples 
deemed to be positive for IgE were also detected in our system as positive.  Titration studies with 
N-Dp2 and C-Dp2 showed the C-Dp2 fusion has a higher capacity to bind IgE, due to the fact 
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that its binding curves are not saturating with Class 6 IgE plasma samples.  Our assays limit of 
detection (between 0.93 and 0.47 kU/L) is slightly higher than that of ImmunoCAP (0.35 kU/L), 
which may only affect quantitation for patients in the very low (Class 1) and the lower end of 
Class 2.  Our method is cost effective, uses flow cytometers, a common instrument in clinical 
labs, and allows for rapid turnaround of samples (~2-3 hours).  Thus, the in vitro yeast display 
system we have created for Der p 2 appears to be useful as a first step diagnostic tool for patients 
with moderate to severe Der p 2 allergies.    
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Figure 4.1: Yeast Display of Der p 2 and MD-2 Aga2 Fusions 
 
(A), N-terminal Aga2 fusion of Der p 2 (N-Dp2) in the yeast display vector pCT302.  DNA 
encoding Der p 2 (green), a c-Myc epitope tag (blue; EQKLISEEDL), and two stop codons was 
purchased (Genescript) and subcloned into pCT302 using restriction sites NheI to XhoI.  The 
pCT302 yeast display vector contains a gene encoding Aga2, one of the subunits of the yeast a-
agglutinin mating receptor that disulfide bonds to Aga-1 on the yeast cell surface, under a 
galactose inducible promoter (GAL1).  The pCT302 vector also contains an influenza 
hemagglutinin epitope tag (HA; YPYDVPDYA) followed by a (GGGGS)3 linker region.  A 
cartoon depicts N-Dp2 on the yeast cell surface during flow cytometric detection of biotinylated 
E. coli LPS (EB-LPS) with a streptavidin (SA) conjugated Alexa Fluor 647.  The pCT302 yeast 
display vector, N-MD-2, and a V-TCR N-L3 were kindly provided by Daiva Mattis (Kranz 
Lab, University of Illinois, Urbana-Champaign).  (B), C-terminal Aga2 fusions of Der p 2 (C-
Dp2) and MD-2 (C-MD-2) in the yeast display vector Y10.  DNA between the restriction sites 
EcoRI and NheI encoding for the Aga2 secretion leader sequence (aa 1-18; black), Der p 2 or 
MD-2 (green), and a c-Myc epitope tag (blue) were purchased from Genescript and subcloned 
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from a pUC57 vector into the Y10  yeast display vector (kind gift from Dr. David Aggen of the 
Kranz lab, University of Illinois Urbana-Champaign).  Y10 enables the production of C-terminal 
Aga2 fusion proteins followed by the HA epitope tag (red) and two stop codons.  A cartoon 
depicts the arrangement of these C-terminal Aga2 fusion proteins on the yeast cell surface during 
detection of LPS binding. 
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Figure 4.2:  HA and c-Myc Epitope Tag Detection Confirms Full-Length Expression of Der p 2 
and MD-2 
 
(A), Flow cytometry detection of anti-HA (orange) and anti-c-Myc (lime) epitope tags expressed 
in N-terminal Aga2 fusion of Der p 2 (N-Dp2) using flow cytometry.  (B), Flow cytometry 
detection of anti-HA bound to C-Dp2 (red), C-MD-2 (dark blue), and the empty Y10 vector (C-
vector; green) compared to anti-HA stained N-Dp2 (orange), N-MD-2 (light blue), and N-L3 
(purple).  Negative control used in all flow cytometry experiments is the N-terminal Aga2 fusion 
of L3 (N-L3) stained with secondary antibody AlexaFluor647 goat anti-mouse (GαM; grey 
filled). 
118 
 
Figure 4.3:  MD-2 Fusion Detection using Anti-MD-2 Antibody (18H10)  
 
(A), Flow cytometry detection using anti-MD-2 antibody (18H10) of N-MD-2 (light blue), but 
not N-Dp2 (orange) or N-L3 (purple).  (B), Flow cytometry detection using anti-MD-2 antibody 
(18H10) of both N-MD-2 (light blue) and C-MD-2 (dark blue).  Negative control used in all flow 
cytometry experiments is the N-terminal Aga2 fusion of L3 (N-L3) stained with secondary 
antibody AlexaFluor647 goat anti-mouse (GαM; grey filled). 
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Figure 4.4:  Anti-Der p 2 Antibodies (1D8, 10E11, DpX) Are Capable of Detecting Yeast 
Displayed Der p 2 Fusions  
 
(A), Anti-Der p 2 antibody (1D8) recognizes N-Dp2 (orange), but not N-MD-2 (light blue) or N-
L3 (purple).  (B), Anti-Der p 2 antibody (10E11) binds C-Dp2 (pink), but not N-Dp2 (green).  
Anti-Der p 2 antibody (1D8) detection of N-Dp2 (orange) and C-Dp2 (red) was included for 
comparison. (C), Anti-Der p 2 antibody (DpX) binds C-Dp2 (orange) similar to the 1D8 
antibody (C-Dp2 1D8; green).  DpX is capable of binding the N-terminal Aga2 fusion of Der p 2 
as well (data not shown).  Negative control used in all flow cytometry experiments is the N-
terminal Aga2 fusion of L3 (N-L3) stained with secondary antibody AlexaFluor647 goat anti-
mouse (GαM; grey filled). 
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Figure 4.5:  Thermal Denaturation Trials of Der p 2 
 
(A), Flow cytometry detection of anti-Der p 2 antibody (1D8) following thermal denaturation (4 
to 100oC) trials of N-Dp2 (red).  Similar results were obtained with Anti-Der p 2 antibodies DpX 
and biotinylated-7A1 (data not shown).  (B), Flow cytometry detection of anti-Der p 2 antibody 
(10E11) following thermal denaturation (4 to 100oC) trials of C-Dp2 (red).  (C), Flow cytometry 
detection of anti-Der p 2 antibody (10E11) following thermal denaturation (4 to 100oC) trials of 
N-Dp2 (red).  (D), Anti-Der f 2 antibody 13A4 binding to N-Dp2 was also screened, and shows 
little to no detection (red). Negative control used in all flow cytometry experiments is the N-
terminal Aga2 fusion of L3 (N-L3) stained with secondary antibody AlexaFluor647 goat anti-
mouse (GαM; grey filled).  All panels A-D show N- and C-terminal Aga2 fusions of Der p 2 do 
not denature with heat. 
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Figure 4.6:  Detection of E. coli LPS Binding to Der p 2 and MD-2 
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(A), Detection of biotinylated E. coli (EB-LPS) binding to N-Dp2 (orange) and N-MD-2 (light 
blue) at greater levels than N-L3 (purple).  Binding curves show N-MD-2 binds EB-LPS better 
than all, and N-Dp2 binds EB-LPS better than most, of the N-terminal Aga2 fusion negative 
control panel proteins.   (B), Detection using an anti-LPS antibody specific for the core 
polysaccharide region of the O111:B4 serotype of E. coli LPS without biotin (O-LPS) indicates 
binding to C-Dp2 (red), C-MD-2 (dark blue), empty Y10 vector (C-vector), N-Dp2 (orange), N-
MD-2 (light blue), and N-L3 (purple).  (C), Purified human CD14 decreases indicated E. coli 
LPS binding to C-Dp2 (comparison of red to pink) or N-Dp2 (comparison of orange and 
maroon).  Similarly, purified human CD14 decreases indicated E. coli LPS binding to the empty 
Y10 vector (C-vector; comparison of dark and light green) and N-L3 (comparison of dark to 
light purple).  Negative control used in all flow cytometry experiments is the N-terminal Aga2 
fusion of L3 (N-L3) stained with secondary antibody AlexaFluor647 goat anti-mouse (GαM; 
grey filled). 
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Figure 4.7:  Detection of Human TLR4 Extracellular Domain Binding to MD-2, but Not Der p 2  
 
(A), Flow cytometry detection of purified human TLR4 using anti-human TLR4 antibody 
(HTA125) indicates binding to N-MD-2 (light blue and dark blue), but not N-Dp2 (orange and 
yellow).  (B), Flow cytometry detection of purified human TLR4 indicates binding to N-MD-2 
(light blue) and C-MD-2 (dark blue), but not N- (orange) or C-terminal (red) Aga2 fusions of 
Der p 2 anti-HA.  Purified human TLR4 binding to the empty Y10 vector (C-vector; green) and 
N-L3 (purple) was not detected. Negative control used in all flow cytometry experiments is the 
N-terminal Aga2 fusion of L3 (N-L3) stained with secondary antibody AlexaFluor647 goat anti-
mouse (GαM; grey filled). 
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Figure 4.8:  Yeast Displayed C-Dp2 Can Detect Der p 2 Specific IgE from Atopic Patient Serum 
 
(A), Flow cytometry of C-Dp2 indicates non-dust mite allergic patient serum in various dilutions 
(1.5, 2.3, and 3.4 fold) does not contain detectable levels of IgE.  Negative control used in all 
flow cytometry experiments is the N-terminal Aga2 fusion of L3 (N-L3) stained with secondary 
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antibody AlexaFluor647 goat anti-mouse (GαM; grey filled). (B), Flow cytometry of C-Dp2 was 
capable of detecting binding of human IgE from one patient serum sample (sample MN; 67.3 
kU/L ImmunoCAP).  (C), Relative fluorescence measurements versus ImmunoCAP values are 
plotted and non-linear least squares fit is shown (n=3).  
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Figure 4.9:  Yeast Displayed Der p 2 Can Detect IgE from Atopic Patient Plasma 
 
(A), Flow cytometry of N-Dp2 indicates detection of IgE from dust mite allergic patient plasma 
G (ImmunoCAP 238.09 kU/L) when diluted.  Negative control used in all flow cytometry 
experiments is the N-terminal Aga2 fusion of L3 (N-L3) stained with secondary antibody 
AlexaFluor647 goat anti-mouse (GαM; grey filled).  Relative fluorescence measurements versus 
ImmunoCAP values are shown below for each sample (n=3).   (B), Flow cytometry C-Dp2 
indicates detection of IgE from dust mite allergic patient plasma G when diluted.  Relative 
fluorescence versus ImmunoCAP values are shown below for each sample (n=3).  
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Figure 4.10:  Yeast Displayed Der p 2 Can Detect IgE from Multiple Atopic Patients 
 
(A), Flow cytometry N-Dp2 indicates detection of IgE from multiple patient samples.  MFI 
measurements versus ImmunoCAP values are shown below for each sample (n=3).  Negative 
control used in all flow cytometry experiments is the N-terminal Aga2 fusion of L3 (N-L3) 
stained with secondary antibody AlexaFluor647 goat anti-mouse (GαM; grey filled).  (B), Flow 
cytometry C-Dp2 indicates detection of IgE from multiple patient samples.  MFI measurements 
versus ImmunoCAP values are shown below for each sample (n=3).  
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CHAPTER 5: 
 
Conclusion 
  
 In this Chapter, we will summarize the major findings of our work, describe the 
significance of our findings, and propose future studies.  Our primary project goal, which we 
achieved, was to solve the x-ray crystal structure of human CD14.  Each stage of crystallography 
from construct design to protein expression and purification to optimizing crystals has a 
multitude of roadblocks that are only heightened by difficulties unique to the expression and 
purification of soluble eukaryotic targets like human CD14.  For example, although E. coli is the 
expression system of choice for crystallographers due to rapid cell growth, low production costs, 
and high purification yield, it was not an option for our work.  During their efforts to determine 
the structure of human CD14, Meng and colleagues detected soluble human CD14 in insoluble 
aggregates with LPS in E. coli, which were not useful for structural studies (135).  Thus, to 
accomplish our goal, we chose to produce human and mouse CD14 proteins using a mammalian 
expression system, which is not a trivial process.  Human cells grow much slower by comparison 
with E. coli, requiring weekly cycles of protein expression and purification over many years to 
obtain sufficient quantities of protein for all of our studies.  Others have also experienced the 
challenge of structure determination of a human target, as evidence in the PDB, where only 24% 
of the 91,190 x-ray structures deposited as of June 2013 are human in origin.  Despite the 
technical challenges, structural studies have long provided a guide to the interpretation of 
functional, biophysical, and mutational data, in order to more fully understand the role of a 
protein in a biological process.  As described in Chapter 1, the discovery of lipopolysaccharide 
as a potent endotoxin sparked studies to determine the order of action and role of each protein in 
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the LPS sensing cascade, which benefitted greatly from extensive x-ray structure studies.  
Information gleaned from the native and ligand bound x-ray structures of BPI, mouse CD14, and 
multiple human and mouse TLR4/MD-2 complexes had a profound impact on our understanding 
of the LPS sensing cascade.  
 Similarly, our x-ray structure of human CD14 described in Chapter 2 extended the 
foundational knowledge provided by the x-ray structure of mouse CD14 (69).  Determining the 
x-ray crystal structure of human CD14 allowed us to determine similarities and differences 
between the two proteins.   As with mouse CD14, we found human CD14 contained 11 leucine 
rich repeats that form a bent solenoid fold.  Although the resolution of our structure fell just 
outside the limit of secondary structure detection, we identified five alpha helices and a parallel 
beta sheet containing eleven beta strands.  Human CD14 also crystallized as a monomer 
counteracting a growing misconception of the need for C-terminal dimerization during LPS 
delivery, which is illustrated by (CD14-LPS)2 in Figure 1.1.  At the N-terminus, we also 
identified a hydrophobic pocket formed by residues in α1 through α5 and 1 through β6 that was 
similar in size to mouse CD14.  During our analysis of this pocket region, we noted an expanded 
pocket diameter and subdivided entrance formed by F49 in α1 and Y82 in α3 rim residues in 
human CD14, which were not present in mouse CD14.  We propose that these rim residues shift 
upon LPS binding.  The fact that the MD-2 pocket is larger relative to CD14, along with the 
knowledge that the MD-2 pocket cannot contain all six acyl chains of E. coli LPS, we predicted 
human CD14 would also be incapable of entirely sequestering all six acyl chains in its N-
terminal hydrophobic pocket.  With that in mind, we analyzed our human CD14 x-ray structure 
and discovered a hydrophobic patch adjacent to the pocket entrance, which may have the 
capacity to stabilize exposed LPS acyl chains.  We also found a solvent exposed hydrophobic 
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patch in the same region of mouse CD14, which may play an analogous role upon ligand 
binding.  Thus, our extensive efforts to solve the x-ray crystal structure of human CD14 have 
provided many important advances in our understanding of the structure itself, the structural 
similarity with mouse CD14, and important properties of the predicted N-terminal LPS binding 
pocket and an adjacent hydrophobic patch, which may spark additional efforts to target CD14 
function as a means to modulate devastating diseases like sepsis. 
 Remaining structural questions include the identification of all molecular interactions 
between LPS and CD14 required for LPS binding and the protein-protein interactions between 
CD14, LBP, and MD-2 necessary for LPS transfer.  To tackle the first gap in knowledge, we 
attempted to obtain a ligand bound crystal structure of human or mouse CD14 as described in 
Chapter 3.  As a prerequisite of the ligand bound structural studies, we showed our purified 
human and mouse CD14 are able to bind LPS and other ligands as measured by native PAGE gel 
shift and ForteBio Octet.  We found both proteins are also bioactive because they are able to 
deliver LPS and stimulate TLR4 dependent IL-8 production in SW620 cells, and human CD14 
was also shown in small gel filtration mixing studies to enable complex formation of 
TLR2/1/OspA catalytically without the need for LBP (188).  Although our purified CD14 
proteins were unable to crystallize in the LPS bound form, we were able to offer these pure, 
bioactive proteins for use in other collaborative studies, including the resolution of molecular 
interactions in MD-2/TLR4/LPS using yeast display (unpublished) and the characterization of 
the catalytic role of CD14 in TLR2/1 agonist delivery (188).  In the future, additional ligands 
could be explored for ligand bound structural studies. 
 We also studied the ligand binding ability of the allergen Der p 2 from D. pteronyssinus, 
which is reported to be an additional TLR4 accessory protein.  As described in Chapter 1, Der p 
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2 is not only processed and displayed for TH2 recognition, stimulating an allergic response, but 
may also act as an adjuvant by mimicking the function of MD-2 in the LPS sensing cascade 
thereby stimulating inflammation.  Since Der p 2 induced allergy and inflammation are both 
implicated in the development of allergic asthma, characterizing the interactions between Der p 
2, LPS, and TLR4 would advance our understanding of the allergic process.  As a first step we 
established two forms of Der p 2 on the surface of yeast, which vary in the location of their 
agglutinin fusion on the N or C-terminus (N-Dp2 and C-Dp2).  One C-terminal MD-2 Aga2 
fusion (C-MD-2) was also established for yeast expression.  We confirmed full length protein 
expression by detecting HA and c-Myc epitope tags using flow cytometry.  We also confirmed 
anti-MD-2 monoclonal antibodies (4H1 and 18H10) were capable of specifically binding yeast 
displayed C-MD-2.  Likewise, a multitude of anti-Der p 2 antibodies recognize both the N- and 
C-terminal Aga2 fusions of Der p 2 with specificity.  We observed detectable interactions 
between E. coli LPS and either N-Dp2, C-Dp2, or C-MD-2 proteins.  We did not reliably detect 
interactions between purified human TLR4 and N-Dp2 or C-Dp2, but we did detect binding to C-
MD-2.  We also attempted to determine if Der p 2 is properly folded on the yeast cell surface 
using thermal denaturation followed by anti-Der p 2 antibody binding studies.  However, we 
could not directly confirm folding using this method because of the thermostability of Der p 2.   
 Using our novel in vitro flow cytometry based system, we showed both N-Dp2 and C-
Dp2 displayed on the surface of yeast were capable of detecting IgE in both allergic patient 
serum and plasma.  Similar to ImmunoCAP IgE detection, we showed our system reliably 
produces a greater fluorescence intensity relative to the amount of IgE in each sample.  
ImmunoCAP can detect Class 1 to Class 6 levels.  Our system has the ability to sense Class 2 to 
Class 6 levels of Der p 2 specific IgE.  C-Dp2 may contain additional IgE binding sites relative 
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to N-Dp2, because binding profiles with N-Dp2 showed saturation and C-Dp2 did not show 
saturation using the patient sample with the highest Class 6 level of IgE.  Thus, our novel 
detection method may offer clinical and research laboratories a cost effective way to monitor 
allergy in patient samples.  Using the power of yeast display to screen large libraries of Der p 2 
mutants could better define IgE or LPS binding epitopes, which may spark pharmaceutical 
intervention in allergic asthma.   
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